Current Concepts in Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

The t(9;22)(q34;q11) or Philadelphia chromosome creates a BCR-ABL1 fusion gene encoding for a chimeric BCR-ABL1 protein. It is present in 3-4% of pediatric acute lymphoblastic leukemia (Ph(+) ALL), and about 25% of adult ALL cases. Prior to the advent of tyrosine kinase inhibitors (TKI), Ph(+) ALL w...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Frontiers in oncology Ročník 4; s. 54
Hlavní autoři: Bernt, Kathrin M., Hunger, Stephen P.
Médium: Journal Article
Jazyk:angličtina
Vydáno: Switzerland Frontiers Media S.A 01.01.2014
Témata:
Acute Lymphoblastic Leukemia
BCR-ABL1
chemotherapy
Hematopoietic Stem Cell Transplantation
Oncology
Tyrosine Kinase Inhibition
hematopoietic stem-cell transplantation
tyrosine kinase inhibition
acute lymphoblastic leukemia
chemotherapy
BCR–ABL1
ISSN:2234-943X, 2234-943X
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Abstract The t(9;22)(q34;q11) or Philadelphia chromosome creates a BCR-ABL1 fusion gene encoding for a chimeric BCR-ABL1 protein. It is present in 3-4% of pediatric acute lymphoblastic leukemia (Ph(+) ALL), and about 25% of adult ALL cases. Prior to the advent of tyrosine kinase inhibitors (TKI), Ph(+) ALL was associated with a very poor prognosis despite the use of intensive chemotherapy and frequently hematopoietic stem-cell transplantation (HSCT) in first remission. The development of TKIs revolutionized the therapy of Ph(+) ALL. Addition of the first generation ABL1 class TKI imatinib to intensive chemotherapy dramatically increased the survival for children with Ph(+) ALL and established that many patients can be cured without HSCT. In parallel, the mechanistic understanding of Ph(+) ALL expanded exponentially through careful mapping of pathways downstream of BCR-ABL1, the discovery of mutations in master regulators of B-cell development such as IKZF1 (Ikaros), PAX5, and early B-cell factor (EBF), the recognition of the complex clonal architecture of Ph(+) ALL, and the delineation of genomic, epigenetic, and signaling abnormalities contributing to relapse and resistance. Still, many important basic and clinical questions remain unanswered. Current clinical trials are testing second generation TKIs in patients with newly diagnosed Ph(+) ALL. Neither the optimal duration of therapy nor the optimal chemotherapy backbone are currently defined. The role of HSCT in first remission and post-transplant TKI therapy also require further study. In addition, it will be crucial to continue to dig deeper into understanding Ph(+) ALL at a mechanistic level, and translate findings into complementary targeted approaches. Expanding targeted therapies hold great promise to decrease toxicity and improve survival in this high-risk disease, which provides a paradigm for how targeted therapies can be incorporated into treatment of other high-risk leukemias.
AbstractList The t(9;22)(q34;q11) or Philadelphia chromosome creates a BCR-ABL1 fusion gene encoding for a chimeric BCR-ABL1 protein. It is present in 3-4% of pediatric acute lymphoblastic leukemia (Ph(+) ALL), and about 25% of adult ALL cases. Prior to the advent of tyrosine kinase inhibitors (TKI), Ph(+) ALL was associated with a very poor prognosis despite the use of intensive chemotherapy and frequently hematopoietic stem-cell transplantation (HSCT) in first remission. The development of TKIs revolutionized the therapy of Ph(+) ALL. Addition of the first generation ABL1 class TKI imatinib to intensive chemotherapy dramatically increased the survival for children with Ph(+) ALL and established that many patients can be cured without HSCT. In parallel, the mechanistic understanding of Ph(+) ALL expanded exponentially through careful mapping of pathways downstream of BCR-ABL1, the discovery of mutations in master regulators of B-cell development such as IKZF1 (Ikaros), PAX5, and early B-cell factor (EBF), the recognition of the complex clonal architecture of Ph(+) ALL, and the delineation of genomic, epigenetic, and signaling abnormalities contributing to relapse and resistance. Still, many important basic and clinical questions remain unanswered. Current clinical trials are testing second generation TKIs in patients with newly diagnosed Ph(+) ALL. Neither the optimal duration of therapy nor the optimal chemotherapy backbone are currently defined. The role of HSCT in first remission and post-transplant TKI therapy also require further study. In addition, it will be crucial to continue to dig deeper into understanding Ph(+) ALL at a mechanistic level, and translate findings into complementary targeted approaches. Expanding targeted therapies hold great promise to decrease toxicity and improve survival in this high-risk disease, which provides a paradigm for how targeted therapies can be incorporated into treatment of other high-risk leukemias.The t(9;22)(q34;q11) or Philadelphia chromosome creates a BCR-ABL1 fusion gene encoding for a chimeric BCR-ABL1 protein. It is present in 3-4% of pediatric acute lymphoblastic leukemia (Ph(+) ALL), and about 25% of adult ALL cases. Prior to the advent of tyrosine kinase inhibitors (TKI), Ph(+) ALL was associated with a very poor prognosis despite the use of intensive chemotherapy and frequently hematopoietic stem-cell transplantation (HSCT) in first remission. The development of TKIs revolutionized the therapy of Ph(+) ALL. Addition of the first generation ABL1 class TKI imatinib to intensive chemotherapy dramatically increased the survival for children with Ph(+) ALL and established that many patients can be cured without HSCT. In parallel, the mechanistic understanding of Ph(+) ALL expanded exponentially through careful mapping of pathways downstream of BCR-ABL1, the discovery of mutations in master regulators of B-cell development such as IKZF1 (Ikaros), PAX5, and early B-cell factor (EBF), the recognition of the complex clonal architecture of Ph(+) ALL, and the delineation of genomic, epigenetic, and signaling abnormalities contributing to relapse and resistance. Still, many important basic and clinical questions remain unanswered. Current clinical trials are testing second generation TKIs in patients with newly diagnosed Ph(+) ALL. Neither the optimal duration of therapy nor the optimal chemotherapy backbone are currently defined. The role of HSCT in first remission and post-transplant TKI therapy also require further study. In addition, it will be crucial to continue to dig deeper into understanding Ph(+) ALL at a mechanistic level, and translate findings into complementary targeted approaches. Expanding targeted therapies hold great promise to decrease toxicity and improve survival in this high-risk disease, which provides a paradigm for how targeted therapies can be incorporated into treatment of other high-risk leukemias.
The t(9;22)(q34;q11) or Philadelphia chromosome that creates a BCR-ABL1 fusion gene encoding for a chimeric BCR-ABL1 protein is present in 3-4% of pediatric acute lymphoblastic leukemia (Ph+ ALL), and about 25% of adult ALL cases. Prior to the advent of tyrosine kinase inhibitors (TKI), Ph+ ALL was associated with a very poor prognosis despite use of intensive chemotherapy and frequently hematopoietic stem cell transplantation (HSCT) in first remission. The development of TKIs revolutionized the therapy of Ph+ ALL. Addition of the first generation ABL1 class TKI imatinib to intensive chemotherapy dramatically increased survival for children with Ph+ ALL and established that many patients can be cured without HSCT. In parallel, the mechanistic understanding of Ph+ ALL expanded exponentially through careful mapping of pathways downstream of BCR-ABL1, the discovery of mutations in master regulators of B-cell development such as IKZF1 (Ikaros), PAX5 and EBF, the recognition of the complex clonal architecture of Ph+ ALL, and the delineation of genomic, epigenetic and signaling abnormalities contributing to relapse and resistance. Still, many important basic and clinical questions remain unanswered. Current clinical trials are testing second generation TKIs in patients with newly diagnosed Ph+ ALL. Neither the optimal duration of therapy nor the optimal chemotherapy backbone are currently defined. The role of HSCT in first remission and post-transplant TKI therapy also require further study. In addition, it will be crucial to continue to dig deeper into understanding Ph+ ALL at a mechanistic level, and translate findings into complementary targeted approaches. Expanding targeted therapies holds great promise to decrease toxicity and improve survival in this high risk disease, which provides a paradigm for how targeted therapies can be incorporated into treatment of other high risk leukemias.
The t(9;22)(q34;q11) or Philadelphia chromosome creates a BCR-ABL1 fusion gene encoding for a chimeric BCR-ABL1 protein. It is present in 3-4% of pediatric acute lymphoblastic leukemia (Ph(+) ALL), and about 25% of adult ALL cases. Prior to the advent of tyrosine kinase inhibitors (TKI), Ph(+) ALL was associated with a very poor prognosis despite the use of intensive chemotherapy and frequently hematopoietic stem-cell transplantation (HSCT) in first remission. The development of TKIs revolutionized the therapy of Ph(+) ALL. Addition of the first generation ABL1 class TKI imatinib to intensive chemotherapy dramatically increased the survival for children with Ph(+) ALL and established that many patients can be cured without HSCT. In parallel, the mechanistic understanding of Ph(+) ALL expanded exponentially through careful mapping of pathways downstream of BCR-ABL1, the discovery of mutations in master regulators of B-cell development such as IKZF1 (Ikaros), PAX5, and early B-cell factor (EBF), the recognition of the complex clonal architecture of Ph(+) ALL, and the delineation of genomic, epigenetic, and signaling abnormalities contributing to relapse and resistance. Still, many important basic and clinical questions remain unanswered. Current clinical trials are testing second generation TKIs in patients with newly diagnosed Ph(+) ALL. Neither the optimal duration of therapy nor the optimal chemotherapy backbone are currently defined. The role of HSCT in first remission and post-transplant TKI therapy also require further study. In addition, it will be crucial to continue to dig deeper into understanding Ph(+) ALL at a mechanistic level, and translate findings into complementary targeted approaches. Expanding targeted therapies hold great promise to decrease toxicity and improve survival in this high-risk disease, which provides a paradigm for how targeted therapies can be incorporated into treatment of other high-risk leukemias.
Author Bernt, Kathrin M.
Hunger, Stephen P.
AuthorAffiliation 1 Department of Pediatrics, University of Colorado School of Medicine and Children’s Hospital Colorado , Aurora, CO , USA
AuthorAffiliation_xml – name: 1 Department of Pediatrics, University of Colorado School of Medicine and Children’s Hospital Colorado , Aurora, CO , USA
Author_xml – sequence: 1
  givenname: Kathrin M.
  surname: Bernt
  fullname: Bernt, Kathrin M.
– sequence: 2
  givenname: Stephen P.
  surname: Hunger
  fullname: Hunger, Stephen P.
BackLink https://www.ncbi.nlm.nih.gov/pubmed/24724051$$D View this record in MEDLINE/PubMed
BookMark eNp1kktr3DAUhUVJadI06-6Kl914opcf2hSC6SMw0Fm0UOhCyNJ1rFS2XEkO5N9Xk0lKEshKF91zvqvHeYuOZj8DQu8J3jDWivPBz3pDMeEbjHHFX6ETShkvBWe_jh7Vx-gsxusswXWFCWZv0DHlDeW4Iifod7eGAHMqugyDJcXCzsUOjFUpWF3sRuuUAbeMVhXdGPzko5-g3Plok72B4kKvCYrt7bSMvncqpmzawvoHJqveodeDchHO7tdT9PPL5x_dt3L7_etld7EtNa9EKmmr-1YrIBUZegqibRplNDMN5wJjQ1ibO4SDodgIIzTkqu4xg1YzjauanaLLA9d4dS2XYCcVbqVXVt5t-HAlVcgHcyCpoKahTIt60JzjVpiW9FWNlVJMAGsy69OBtaz9BEbnpwnKPYE-7cx2lFf-RjLREIpZBny8BwT_d4WY5GSjBufUDH6NklQcE9LkO2Xph8ez_g95-J0sqA4CHXyMAQapbVLJ-v1o6yTBch8EuQ-C3AdB3gUh-86f-R7QLzn-ARC5twA
CitedBy_id crossref_primary_10_1002_cncr_35481
crossref_primary_10_1080_07391102_2021_1935320
crossref_primary_10_1186_s13039_014_0060_0
crossref_primary_10_7759_cureus_54154
crossref_primary_10_1007_s12032_014_0360_6
crossref_primary_10_1097_MPH_0000000000001521
crossref_primary_10_3389_fped_2017_00248
crossref_primary_10_1093_bib_bbaf259
crossref_primary_10_3389_fonc_2021_632231
crossref_primary_10_1038_nrclinonc_2015_38
crossref_primary_10_61882_hsm_4_3_207
crossref_primary_10_1186_s12864_021_08094_z
crossref_primary_10_1146_annurev_cancerbio_030518_055524
crossref_primary_10_1186_s12964_023_01039_x
crossref_primary_10_1186_s13045_015_0184_7
crossref_primary_10_3389_fped_2022_837656
crossref_primary_10_1124_pr_118_016824
crossref_primary_10_1186_s13045_016_0270_5
crossref_primary_10_3390_ijms22126411
crossref_primary_10_1080_14656566_2021_1931683
crossref_primary_10_1038_s41375_025_02608_4
crossref_primary_10_1016_j_bbmt_2018_12_007
crossref_primary_10_1093_jjco_hyad156
crossref_primary_10_1017_erm_2021_6
crossref_primary_10_1016_j_critrevonc_2025_104806
crossref_primary_10_1016_j_leukres_2017_05_021
crossref_primary_10_3389_fonc_2021_588101
crossref_primary_10_1182_bloodadvances_2023009808
crossref_primary_10_1111_bjh_17879
crossref_primary_10_1158_0008_5472_CAN_18_1703
crossref_primary_10_1038_s41598_019_39926_4
crossref_primary_10_1111_imr_13180
crossref_primary_10_1182_blood_2017_06_743252
crossref_primary_10_1038_s41417_022_00491_0
crossref_primary_10_1111_cei_12812
crossref_primary_10_1002_pbc_31514
crossref_primary_10_1093_stcltm_szac066
crossref_primary_10_1016_j_phrs_2015_07_010
crossref_primary_10_1155_2015_612567
crossref_primary_10_29333_ejgm_13386
crossref_primary_10_1080_10428194_2016_1196814
crossref_primary_10_1007_s12288_019_01214_6
crossref_primary_10_1111_bph_16149
crossref_primary_10_3390_cancers13081847
crossref_primary_10_1002_pbc_29441
crossref_primary_10_1016_j_snb_2020_128071
crossref_primary_10_1016_j_pharmthera_2024_108742
crossref_primary_10_1371_journal_pone_0243657
crossref_primary_10_1038_onc_2017_210
crossref_primary_10_1002_stem_3263
crossref_primary_10_1007_s00277_019_03713_y
crossref_primary_10_1016_j_exphem_2019_05_003
crossref_primary_10_1016_j_cancergen_2023_07_002
crossref_primary_10_1007_s40124_015_0078_8
crossref_primary_10_3390_biomedicines12122739
crossref_primary_10_1016_j_genrep_2016_07_008
crossref_primary_10_1371_journal_pone_0256801
crossref_primary_10_1002_cnr2_1452
crossref_primary_10_3390_cells10123349
crossref_primary_10_1038_leu_2016_269
crossref_primary_10_3390_jcm10173792
crossref_primary_10_1002_pbc_26242
crossref_primary_10_1002_pbc_28543
crossref_primary_10_1016_j_anpedi_2021_02_015
crossref_primary_10_1177_1533033820928436
crossref_primary_10_3390_ijms23052755
crossref_primary_10_3928_00904481_20150710_10
crossref_primary_10_3390_molecules25235775
crossref_primary_10_3390_ijms21103409
crossref_primary_10_1111_cas_14849
crossref_primary_10_1016_j_anpede_2021_02_016
crossref_primary_10_1080_07853890_2018_1564359
crossref_primary_10_3390_cancers17152456
crossref_primary_10_12688_hrbopenres_13822_1
crossref_primary_10_1007_s00277_024_05830_9
crossref_primary_10_1111_bjh_13896
crossref_primary_10_12688_hrbopenres_13822_2
crossref_primary_10_1002_cbin_10994
crossref_primary_10_1002_jha2_514
crossref_primary_10_1084_jem_20190589
crossref_primary_10_3390_ijms21165776
crossref_primary_10_1016_j_yao_2024_11_004
crossref_primary_10_1097_MPH_0000000000000582
crossref_primary_10_3390_ijms25168831
crossref_primary_10_1002_cam4_70780
crossref_primary_10_1016_j_bbamcr_2023_119467
crossref_primary_10_1517_17460441_2014_956720
crossref_primary_10_1007_s10928_018_9578_9
crossref_primary_10_1016_j_genrep_2016_11_004
crossref_primary_10_3390_cancers10040110
crossref_primary_10_1182_blood_2019001815
Cites_doi 10.1038/sj.leu.2401124
10.3324/haematol.2012.072470
10.1200/JCO.2008.21.2514
10.1038/nm0596-561
10.1038/sj.onc.1209775
10.1038/leu.2009.194
10.1371/journal.pone.0040934
10.1177/1947601910372232
10.1016/j.ccr.2009.09.028
10.1038/leu.2012.204
10.1016/S0165-4608(01)00507-6
10.1182/blood-2006-11-052373
10.1038/bcj.2011.13
10.1016/j.bcmd.2013.10.003
10.1182/blood-2011-04-345595
10.1016/j.coi.2010.02.004
10.1056/NEJMoa051140
10.1016/j.cancergencyto.2009.06.013
10.1182/blood-2008-08-173963
10.1056/NEJMoa0912614
10.1038/nature09733
10.1073/pnas.0602030103
10.1016/j.immuni.2008.05.015
10.1182/asheducation-2005.1.188
10.1182/blood-2012-03-415448
10.1172/JCI66203
10.1128/MCB.13.12.7587
10.1111/ejh.12202
10.1038/ng.430
10.1158/2159-8290.CD-12-0548
10.1038/300765a0
10.1056/NEJMoa0808253
10.1016/S0959-437X(02)00013-8
10.1182/blood-2010-10-313692
10.1038/leu.2013.112
10.1182/blood-2008-04-148791
10.1182/blood-2003-04-1271
10.1016/j.leukres.2011.07.034
10.1038/sj.leu.2404320
10.1016/S0171-2985(97)80043-5
10.1056/NEJMe0809819
10.1016/j.exphem.2012.11.004
10.1074/jbc.271.49.31704
10.1128/MCB.00224-10
10.3109/10428194.2010.546919
10.1111/j.1365-2141.2011.08783.x
10.1182/blood-2003-08-2958
10.1038/nature08675
10.1038/leu.2012.363
10.1200/JCO.2008.19.8853
10.1038/sj.leu.2403257
10.1182/blood-2006-02-002824
10.1200/JCO.2012.46.8280
10.1182/blood-2011-03-341412
10.1016/j.immuni.2004.11.004
10.1007/s12185-012-1026-9
10.1038/sj.onc.1206008
10.1182/blood-2002-06-1756
10.2165/00129785-200404050-00006
10.1084/jem.189.9.1399
10.1200/JCO.2010.30.7231
10.1159/000069438
10.1016/0092-8674(94)90079-5
10.1053/shem.2003.50034
10.1182/blood.V77.2.324.324
10.1182/blood.V99.8.2957
10.1093/emboj/cdf562
10.1182/blood.V86.12.4603.bloodjournal86124603
10.1038/nature05690
10.3324/haematol.2009.020792
10.1016/0092-8674(91)90148-R
10.1172/JCI33337
10.1158/0008-5472.CAN-06-4312
10.1038/nature06159
10.1182/blood-2008-07-168773
10.1038/ng.2754
10.1182/blood-2008-02-140665
10.1016/j.ccr.2007.08.011
10.1038/16476
10.1182/blood-2009-11-252155
10.1056/NEJM200104053441402
10.1128/MCB.11.4.1785
10.1158/0008-5472.CAN-05-0259
10.1038/bmt.2008.296
10.1056/NEJMoa1306494
10.1124/mol.65.6.1485
10.1182/blood-2007-09-112631
10.1038/sj.leu.2403886
10.1038/bmt.2008.441
10.1182/blood.V93.7.2380
10.1182/blood-2007-08-109330
10.1002/ajh.23442
10.1038/sj.leu.2403714
10.1182/blood-2004-04-1398
10.1128/MCB.22.9.2906-2917.2002
10.1101/gad.1673908
10.1016/j.immuni.2009.01.014
10.1016/0092-8674(94)90407-3
10.1038/sj.thj.6200235
10.1038/sj.onc.1204202
10.2165/11594740-000000000-00000
10.1038/nature09727
10.1056/NEJMoa1002315
10.1038/leu.2014.30
10.1128/MCB.11.9.4710
10.1073/pnas.022412699
10.1182/blood-2012-01-401687
10.1002/pbc.22945
10.1016/j.dnarep.2006.05.021
10.1038/leu.2012.324
10.1038/ng.463
10.1182/blood-2009-12-261586
10.1186/1756-8722-5-29
10.1016/j.bcp.2007.12.021
10.1093/jnci/djn188
10.1001/jama.2010.1862
10.1084/jem.20101947
10.1128/MCB.9.3.1263
10.1182/blood.V101.2.690
10.1038/leu.2012.352
10.1128/MCB.24.22.10058-10071.2004
10.1074/jbc.M109.090043
10.1053/j.seminhematol.2006.01.007
10.1016/0092-8674(93)90689-N
10.1002/ajh.21615
10.1126/science.2406902
10.1038/onc.2008.330
10.1182/blood-2005-09-3596
10.1038/leu.2010.87
10.1016/j.ccr.2013.10.022
10.1074/jbc.C000126200
10.1038/sj.leu.2401437
10.1038/344251a0
10.2165/00003495-200161120-00009
10.1016/j.bcp.2013.02.017
10.1093/jnci/djt042
10.1126/science.2408149
10.3324/haematol.2013.085175
10.1182/blood.V99.9.3472
10.1182/asheducation-2012.1.122
10.1038/nature01587
10.1158/1078-0432.CCR-11-1227
10.1073/pnas.0606509103
10.1182/blood-2002-01-0288
10.1038/leu.2010.287
10.1016/j.coi.2010.02.003
10.1200/JCO.2010.30.1325
10.1182/blood.V120.21.137.137
10.1182/blood-2006-04-019836
10.1126/science.1164266
10.1182/blood-2011-11-394221
10.1177/1947601912458584
10.1038/sj.leu.2403060
10.1182/blood-2009-09-241513
10.1182/blood.V116.21.2144.2144
10.1002/j.1460-2075.1989.tb03358.x
10.1182/blood-2004-07-2528
10.1038/leu.2010.257
10.1038/ni.1617
10.1128/MCB.9.5.1866
10.1158/1078-0432.CCR-06-1516
10.1056/NEJMoa022457
10.1038/nm.2430
10.1038/nature09883
10.1038/sj.leu.2402778
10.1182/blood-2005-11-4386
10.4161/cbt.4.7.1826
10.1182/blood.V98.6.1773
10.4331/wjbc.v2.i6.108
10.1200/JCO.2012.47.6770
10.1182/blood-2012-12-475483
10.1016/j.leukres.2013.04.022
10.1158/0008-5472.CAN-06-1199
10.1038/ng.432
10.1038/nature06866
10.1002/ajh.10227
10.1002/ijc.23467
10.1016/j.hoc.2009.07.001
10.1200/JCO.2011.34.8144
10.1016/j.ccr.2009.12.050
10.1111/j.1365-2141.2012.09039.x
10.1182/blood.V85.8.2013.bloodjournal8582013
10.1074/jbc.272.52.33260
10.1038/nm.2415
10.1146/annurev.genom.3.032802.115046
10.1182/blood-2007-03-066936
10.1016/S1470-2045(12)70377-7
10.1182/blood-2011-01-331181
10.1158/0008-5472.CAN-08-1008
10.1002/1521-4141(200203)32:3720::AID-IMMU7203.0.CO;2-P
10.1016/S0092-8674(00)81702-X
10.1016/S1470-2045(12)70580-6
10.1200/JCO.2005.03.2177
10.1084/jem.20110304
10.1182/blood-2006-03-011908
10.1371/journal.pone.0070608
10.1182/blood-2006-10-052746
10.1002/pbc.22484
10.1016/S1535-6108(02)00074-0
10.1038/leu.2012.5
10.3324/haematol.2010.034173
10.1016/0092-8674(95)90277-5
10.1002/cncr.23666
10.1038/sj.onc.1210979
10.1038/ng1343
10.1038/ng.2532
10.1038/376263a0
10.1002/(SICI)1097-0215(1998)78:11+35::AID-IJC113.3.CO;2-9
10.1182/blood-2003-01-0154
10.1159/000228587
10.1016/j.ccr.2012.06.005
10.1182/blood-2007-02-073528
10.1200/JCO.2008.21.6408
10.3324/haematol.2012.073965
10.1016/j.ccr.2006.09.006
10.1182/blood.V99.2.472
10.1182/blood.V96.2.664
10.1084/jem.183.3.811
10.1182/blood-2008-06-165027
10.1002/ajh.23624
10.1182/blood.V97.2.572
10.1182/blood-2011-05-351403
10.1038/leu.2012.155
10.1182/blood-2010-03-275347
10.1002/mpo.10087
10.1182/blood-2012-04-422691
10.1084/jem.190.9.1201
10.1038/nchembio760
10.1016/S1074-7613(00)80269-1
10.1056/NEJM200004063421402
10.1182/blood-2011-07-366542
10.1056/NEJMoa040465
10.1038/243290a0
10.1016/0092-8674(91)90521-Y
10.1101/gad.184341.111
10.1016/0092-8674(95)90170-1
10.1038/leu.2009.135
10.1038/ng.585
10.1038/ni1454
ContentType Journal Article
Copyright Copyright © 2014 Bernt and Hunger. 2014
Copyright_xml – notice: Copyright © 2014 Bernt and Hunger. 2014
DBID AAYXX
CITATION
NPM
7X8
5PM
DOA
DOI 10.3389/fonc.2014.00054
DatabaseName CrossRef
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

PubMed
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2234-943X
ExternalDocumentID oai_doaj_org_article_292d723c96fc44089d81b560aaa39e37
PMC3971203
24724051
10_3389_fonc_2014_00054
Genre Journal Article
Review
GroupedDBID 53G
5VS
9T4
AAFWJ
AAKDD
AAYXX
ACGFO
ACGFS
ADBBV
ADRAZ
AFPKN
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
CITATION
DIK
EBS
EJD
EMOBN
GROUPED_DOAJ
GX1
HYE
KQ8
M48
M~E
OK1
PGMZT
RNS
RPM
ACXDI
IPNFZ
NPM
RIG
7X8
5PM
ID FETCH-LOGICAL-c459t-28cb8cae151fb2e9877adc3d744900d13815114ed20d9d9ceed26b03e8c3c0563
IEDL.DBID DOA
ISICitedReferencesCount 108
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000218397400052&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 2234-943X
IngestDate Fri Oct 03 12:37:44 EDT 2025
Tue Sep 30 16:58:54 EDT 2025
Fri Sep 05 09:34:57 EDT 2025
Thu Apr 03 06:56:19 EDT 2025
Tue Nov 18 22:16:59 EST 2025
Sat Nov 29 04:56:52 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords hematopoietic stem-cell transplantation
tyrosine kinase inhibition
acute lymphoblastic leukemia
chemotherapy
BCR–ABL1
Language English
License This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c459t-28cb8cae151fb2e9877adc3d744900d13815114ed20d9d9ceed26b03e8c3c0563
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
Edited by: Mignon Lee-Cheun Loh, University of California San Francisco, USA
Reviewed by: Anthony V. Moorman, Newcastle University, UK; Bill H. Chang, Oregon Health and Science University, USA
This article was submitted to Pediatric Oncology, a section of the journal Frontiers in Oncology.
OpenAccessLink https://doaj.org/article/292d723c96fc44089d81b560aaa39e37
PMID 24724051
PQID 1540117815
PQPubID 23479
ParticipantIDs doaj_primary_oai_doaj_org_article_292d723c96fc44089d81b560aaa39e37
pubmedcentral_primary_oai_pubmedcentral_nih_gov_3971203
proquest_miscellaneous_1540117815
pubmed_primary_24724051
crossref_citationtrail_10_3389_fonc_2014_00054
crossref_primary_10_3389_fonc_2014_00054
PublicationCentury 2000
PublicationDate 2014-01-01
PublicationDateYYYYMMDD 2014-01-01
PublicationDate_xml – month: 01
  year: 2014
  text: 2014-01-01
  day: 01
PublicationDecade 2010
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
PublicationTitle Frontiers in oncology
PublicationTitleAlternate Front Oncol
PublicationYear 2014
Publisher Frontiers Media S.A
Publisher_xml – name: Frontiers Media S.A
References Iacobucci (B93) 2009; 114
Chen (B117) 2012; 119
Pfeifer (B169) 2007; 110
Mahon (B1) 2012; 2012
Shah (B88) 2013; 45
Mullighan (B99) 2009; 360
Nahar (B190) 2011; 118
Klejman (B65) 2002; 21
Martinelli (B94) 2009; 27
Schaniel (B126) 2002; 99
Million (B29) 2000; 96
Ozvegy-Laczka (B112) 2004; 65
Burger (B176) 2005; 4
Park (B134) 2003; 423
Druker (B161) 2001; 61
Cerchietti (B251) 2010; 17
Puttini (B17) 2006; 66
Ye (B248) 2008; 75
Primo (B144) 2005; 19
Hogan (B203) 2011; 118
Rives (B217) 2011; 154
Redaelli (B245) 2009; 27
Mullighan (B193) 2008; 322
Caye (B101) 2013; 98
Familiades (B121) 2009; 23
Berman (B234) 2006; 354
Sattler (B37) 2003; 40
Kharas (B41) 2008; 118
Ramirez (B107) 2010; 22
Lee (B158) 2005; 19
Wassmann (B164) 2004; 103
Soverini (B167) 2006; 12
Chang (B38) 2012; 157
Weston (B77) 2013; 31
Carlesso (B49) 1996; 183
Iacobucci (B97) 2008; 112
Pene-Dumitrescu (B71) 2008; 27
Cazzaniga (B100) 2011; 118
Roberts (B75) 2012; 22
Lionberger (B68) 2000; 275
Wei (B56) 2006; 10
Cobaleda (B122) 2007; 8
Heltemes-Harris (B130) 2011; 208
Hof (B201) 2011; 29
Hurtz (B189) 2011; 208
Valk (B196) 2004; 350
Garcia-Manero (B146) 2002; 8
Urbanek (B123) 1994; 79
Coon (B233) 2013; 88
Sanders (B238) 2005; 105
Mrozek (B5) 2009; 23
Lugo (B10) 1990; 247
Aplenc (B225) 2011; 29
Sherborne (B89) 2010; 42
Tao (B51) 2008; 27
Samanta (B183) 2010; 1
Hobernicht (B236) 2011; 56
Duy (B188) 2011; 473
Wilson (B69) 2002; 21
Burke (B241) 2009; 43
Cheng (B58) 1998; 95
Kuster (B208) 2011; 117
Donato (B182) 2003; 101
Prasad (B82) 2010; 115
de Labarthe (B162) 2007; 109
Zhang (B119) 2011; 118
Boyerinas (B212) 2013; 121
Adrian (B36) 2006; 2
Saito (B185) 2007; 12
Schaniel (B125) 2002; 99
Mullighan (B137) 2008; 22
Tefferi (B232) 2013; 27
Stanglmaier (B66) 2003; 17
Nichogiannopoulou (B103) 1999; 190
Ottmann (B228) 2013; 27
Malin (B106) 2010; 22
Schwab (B136) 2013; 98
Iacobucci (B149) 2011; 17
Lowe (B133) 2003; 13
Mian (B34) 2009; 23
Pene-Dumitrescu (B73) 2010; 285
Kim (B231) 2010; 55
Figueroa (B151) 2013; 123
Iacobucci (B115) 2012; 7
Ko (B174) 2002; 71
Goga (B44) 1995; 82
Lin (B87) 2014; 52
Carter (B145) 2001; 97
Franz (B25) 1989; 8
Loughran (B198) 2008; 9
Beissert (B33) 2008; 122
Irwin (B63) 2013; 8
Foa (B172) 2011; 118
Suryanarayan (B24) 1991; 77
Pfeifer (B42) 2012; 26
Georgopoulos (B98) 1994; 79
Thomas (B157) 2004; 103
Arico (B4) 2010; 28
Boggs (B108) 1998; 16
Li (B22) 1999; 189
Redig (B43) 2011; 52
Barr (B235) 2010; 55
Hu (B47) 2004; 36
Burke (B240) 2009; 44
Rowley (B20) 1973; 243
Chen (B244) 2012; 5
Voncken (B79) 1995; 86
Georgopoulos (B128) 2009; 360
Bhatla (B148) 2012; 119
Diouf (B207) 2011; 17
Trevino (B84) 2009; 41
Larson (B6) 2006; 43
Wang (B102) 1996; 5
Hoelbl (B46) 2006; 107
Modi (B45) 2011; 25
O’Brien (B14) 2003; 348
Jacobs (B132) 1999; 397
Bhojwani (B204) 2006; 108
Hu (B74) 2006; 103
Schultz (B2) 2009; 27
Soverini (B171) 2011; 96
Eppert (B194) 2011; 17
Xu (B90) 2013; 105
Ma (B114) 2010; 30
Klyuchnikov (B242) 2009; 122
Sill (B139) 1995; 85
Kuiper (B192) 2010; 24
Danhauser-Riedl (B67) 1996; 56
Krivtsov (B197) 2013; 27
Yang (B54) 2014; 92
Bhojwani (B206) 2013; 14
Yu (B214) 2011; 1
Samanta (B52) 2011; 25
Pendergast (B61) 1993; 75
Druker (B11) 1996; 2
Branford (B166) 2002; 99
Mullighan (B92) 2008; 453
Kirstetter (B113) 2002; 32
Lewitzky (B60) 2001; 20
Benjamini (B223) 2013; 89
Gioia (B219) 2011; 118
McWhirter (B27) 1993; 13
Fernandez de Mattos (B187) 2004; 24
Wu (B181) 2008; 100
Trowbridge (B154) 2012; 26
Bokemeyer (B210) 2013
Kantarjian (B15) 2010; 362
He (B28) 2002; 99
Eads (B152) 2002; 62
Tonnelle (B96) 2003; 4
Krentz (B150) 2013; 27
Maru (B30) 1991; 67
O’Hare (B247) 2009; 16
Winandy (B109) 1995; 83
Linabery (B85) 2013; 37
Warmuth (B70) 2003; 101
Kelly (B111) 2002; 3
Ilaria (B3) 2005
Hantschel (B26) 2012; 3
Broske (B155) 2009; 41
McLaughlin (B23) 1989; 9
Yang (B202) 2008; 112
Welschinger (B213) 2013; 41
Chu (B39) 2007; 67
Delannoy (B163) 2006; 20
Lopez (B104) 2002; 99
Chevallier (B191) 2004; 89
Walker (B186) 2007; 26
Slayton (B226) 2012; 120
Rebucci (B205) 2013; 85
O’Hare (B53) 2005; 65
O’Hare (B246) 2007; 110
Kim (B138) 2009; 195
Illmer (B177) 2004; 18
Loh (B76) 2013; 121
Dias (B116) 2008; 29
Druker (B12) 2001; 344
Maloney (B135) 1998; 12
Frank (B48) 1996; 10
Trinh (B153) 2002; 22
Wassmann (B160) 2006; 108
Ramakers-van Woerden (B179) 2002; 38
Maude (B184) 2012; 120
Vignetti (B156) 2007; 109
Kastner (B110) 2011; 2
Barrett (B57) 2012; 14
Carpenter (B239) 2007; 109
Schultz (B216) 2014
Kohno (B140) 2006; 5
Zwaan (B224) 2013; 31
Jones (B175) 2008; 112
Saglio (B16) 2010; 362
Nakamura (B143) 1999; 13
Gentles (B195) 2010; 304
Jones (B165) 2008; 113
Burger (B178) 2004; 104
Iwama (B131) 2004; 21
Papaemmanuil (B83) 2009; 41
Arico (B215) 2000; 342
Ottmann (B220) 2007; 110
de Klein (B21) 1982; 300
Lilly (B221) 2010; 85
Porkka (B218) 2008; 112
Nowell (B19) 1960; 25
Maloney (B147) 1999; 93
Iacobucci (B120) 2010; 95
Pastorczak (B81) 2011; 35
Lanza (B199) 1995; 9
Holmfeldt (B200) 2013; 45
Mullighan (B118) 2007; 446
Zhang (B35) 2010; 463
Wu (B72) 2008; 111
Kardinal (B59) 2001; 98
Castillo (B230) 2010; 116
Mullighan (B211) 2011; 471
Druker (B13) 2001; 344
Biondi (B91) 2012; 13
Hofmann (B170) 2003; 102
Kastner (B86) 2013; 3
Atkinson (B237) 1998; 11
Usuki (B229) 2012; 95
Dupuis (B95) 2013; 27
Daley (B8) 1990; 247
Mahon (B180) 2008; 68
Sattler (B62) 2002; 1
Warmuth (B64) 1997; 272
Lugo (B78) 1989; 9
Cerchietti (B250) 2009; 113
Ng (B105) 2009; 30
Williams (B141) 2006; 103
Chu (B40) 2004; 103
Yanada (B159) 2006; 24
La Starza (B173) 2002; 132
Sadelain (B249) 2013; 3
Ilaria (B50) 1996; 271
Jones (B168) 2010; 115
Notta (B80) 2011; 469
Pfeifer (B243) 2013; 27
Kelliher (B7) 1991; 11
Cortes (B18) 2013; 369
Muller (B31) 1991; 11
Piovan (B55) 2013; 24
Nutt (B124) 1997; 198
Ravandi (B222) 2010; 116
Fleury (B209) 2004; 4
Gutierrez (B142) 2003; 17
Heisterkamp (B9) 1990; 344
Slayton (B227) 2012; 59
Cobaleda (B127) 2007; 449
Pendergast (B32) 1991; 66
Lin (B129) 1995; 376
21946537 - Nat Med. 2011 Sep 25;17(10):1298-303
10544193 - J Exp Med. 1999 Nov 1;190(9):1201-14
20525995 - N Engl J Med. 2010 Jun 17;362(24):2260-70
21248843 - Nature. 2011 Jan 20;469(7330):362-7
11781227 - Blood. 2002 Jan 15;99(2):472-8
12124177 - Cancer Cell. 2002 Jun;1(5):479-92
17496201 - Blood. 2007 Oct 1;110(7):2309-15
17213285 - Blood. 2007 May 1;109(9):3676-8
19129520 - N Engl J Med. 2009 Jan 29;360(5):470-80
15930265 - Cancer Res. 2005 Jun 1;65(11):4500-5
23358883 - Am J Blood Res. 2013;3(1):1-13
11154239 - Blood. 2001 Jan 15;97(2):572-4
24241490 - Haematologica. 2014 Apr;99(4):706-14
22699455 - Leukemia. 2013 Feb;27(2):295-304
18704194 - J Clin Invest. 2008 Sep;118(9):3038-50
20534699 - Haematologica. 2010 Oct;95(10 ):1683-90
7718873 - Blood. 1995 Apr 15;85(8):2013-6
11964322 - Blood. 2002 May 1;99(9):3472-5
22868967 - Leukemia. 2013 Feb;27(2):503-7
16415863 - Nat Chem Biol. 2006 Feb;2(2):95-102
12447959 - Am J Hematol. 2002 Dec;71(4):291-9
23212150 - Leukemia. 2013 Jun;27(6):1254-62
23692655 - Leuk Res. 2013 Aug;37(8):936-42
1875948 - Mol Cell Biol. 1991 Sep;11(9):4710-6
17077147 - Proc Natl Acad Sci U S A. 2006 Nov 7;103(45):16870-5
20207529 - Curr Opin Immunol. 2010 Apr;22(2):177-84
18674933 - Immunity. 2008 Aug 15;29(2):217-27
17062730 - Blood. 2007 Feb 15;109(4):1408-13
22955920 - Blood. 2012 Oct 25;120(17 ):3510-8
11929764 - Blood. 2002 Apr 15;99(8):2760-6
20566697 - Mol Cell Biol. 2010 Sep;30(17):4149-58
22299775 - Br J Haematol. 2012 May;157(4):507-10
21931113 - Blood. 2011 Dec 15;118(25):6521-8
21680795 - Blood. 2011 Sep 15;118(11):3080-7
21224468 - Blood. 2011 Mar 3;117(9):2658-67
21889209 - Leuk Res. 2011 Nov;35(11):1534-6
2747638 - Mol Cell Biol. 1989 May;9(5):1866-74
8758931 - Cancer Res. 1996 Aug 1;56(15):3589-96
20042726 - Blood. 2010 Mar 4;115(9):1765-7
23435357 - Biochem Pharmacol. 2013 May 1;85(9):1219-26
16618932 - Proc Natl Acad Sci U S A. 2006 Apr 25;103(17):6688-93
10224280 - J Exp Med. 1999 May 3;189(9):1399-412
12592324 - Leukemia. 2003 Feb;17(2):283-9
23715577 - J Clin Oncol. 2013 Jul 1;31(19):2460-8
21593872 - Nature. 2011 May 19;473(7347):384-8
21177505 - JAMA. 2010 Dec 22;304(24):2706-15
21390130 - Nature. 2011 Mar 10;471(7337):235-9
20131302 - Am J Hematol. 2010 Mar;85(3):164-70
21193419 - Haematologica. 2011 Apr;96(4):552-7
23921123 - J Clin Invest. 2013 Jul;123(7):3099-111
19204709 - Bone Marrow Transplant. 2009 Aug;44(3):169-74
21765975 - World J Biol Chem. 2011 Jun 26;2(6):108-14
20452982 - J Biol Chem. 2010 Jul 9;285(28):21446-57
21298759 - Pediatr Blood Cancer. 2011 Apr;56(4):671-3
20798787 - Genes Cancer. 2010 Apr;1(4):346-59
16616046 - Semin Hematol. 2006 Apr;43(2):126-33
20227268 - Curr Opin Immunol. 2010 Apr;22(2):168-76
15454481 - Blood. 2005 Feb 1;105(3):1348-54
22845486 - Paediatr Drugs. 2012 Oct 1;14(5):299-316
19075254 - J Clin Oncol. 2009 Jan 20;27(3):469-71
11805317 - Proc Natl Acad Sci U S A. 2002 Jan 22;99(2):602-7
15970668 - Cancer Biol Ther. 2005 Jul;4(7):747-52
10749961 - N Engl J Med. 2000 Apr 6;342(14):998-1006
7585946 - Cell. 1995 Oct 20;83(2):289-99
18519632 - Genes Dev. 2008 Jun 1;22(11):1411-5
1657398 - Cell. 1991 Nov 1;67(3):459-68
18235045 - Blood. 2008 Apr 1;111(7):3821-9
16819511 - Oncogene. 2007 Jan 11;26(2):224-33
14551133 - Blood. 2004 Jun 15;103(12):4396-407
23589674 - Blood. 2013 Jun 13;121(24):4821-31
7596184 - Leukemia. 1995 Jun;9(6):955-9
15531467 - Haematologica. 2004 Nov;89(11):1399-401
14427847 - J Natl Cancer Inst. 1960 Jul;25:85-109
12750728 - Hematol J. 2003;4(2):104-9
17440452 - Nat Immunol. 2007 May;8(5):463-70
15084694 - N Engl J Med. 2004 Apr 15;350(16):1617-28
23508010 - Haematologica. 2013 Jul;98 (7):1081-8
14724652 - Leukemia. 2004 Mar;18(3):401-8
17189410 - Clin Cancer Res. 2006 Dec 15;12(24):7374-9
8541551 - Blood. 1995 Dec 15;86(12):4603-11
15462611 - Am J Pharmacogenomics. 2004;4(5):331-41
17851532 - Nature. 2007 Sep 27;449(7161):473-7
12393636 - Blood. 2003 Jan 15;101(2):664-72
17119111 - Blood. 2007 Apr 1;109(7):2791-3
23835704 - J Clin Oncol. 2013 Sep 1;31(25):e413-6
19131438 - N Engl J Med. 2009 Jan 29;360(5):524-6
18577747 - J Natl Cancer Inst. 2008 Jul 2;100(13):926-39
20525993 - N Engl J Med. 2010 Jun 17;362(24):2251-9
20466853 - Blood. 2010 Sep 23;116(12):2070-7
24112092 - Eur J Haematol. 2014 Feb;92(2):111-20
24180494 - N Engl J Med. 2013 Nov 7;369(19):1783-96
24441288 - Leukemia. 2014 Jul;28(7):1467-71
18455151 - Biochem Pharmacol. 2008 Jun 1;75(11):2080-91
19798092 - Leukemia. 2009 Dec;23(12):2242-7
10849448 - J Biol Chem. 2000 Jun 16;275(24):18581-5
17114238 - Cancer Res. 2006 Dec 1;66(23):11314-22
18477770 - Blood. 2008 Aug 15;112(4):1005-12
20445578 - Leukemia. 2010 Jul;24(7):1258-64
15098032 - Nat Genet. 2004 May;36(5):453-61
18768390 - Blood. 2008 Nov 15;112(10):4178-83
8892675 - Leukemia. 1996 Nov;10(11):1724-30
23233570 - Hematology Am Soc Hematol Educ Program. 2012;2012:122-8
16493008 - Blood. 2006 Jun 15;107(12):4898-906
23212523 - Blood. 2013 Jan 17;121(3):485-8
23065506 - Haematologica. 2013 Apr;98(4):597-601
19684604 - Nat Genet. 2009 Sep;41(9):1006-10
16034462 - Leukemia. 2005 Sep;19(9):1509-16
21072043 - Leukemia. 2011 Feb;25(2):305-12
18809762 - Blood. 2008 Dec 15;112(13):5190-2
21960589 - Blood. 2011 Nov 17;118(20):5559-64
22682059 - J Hematol Oncol. 2012 Jun 08;5:29
18794796 - Oncogene. 2008 Nov 27;27(56):7055-69
23604230 - Leukemia. 2013 Sep;27(9):1939-40
11535511 - Blood. 2001 Sep 15;98(6):1773-81
21873988 - Nat Med. 2011 Aug 28;17(9):1086-93
11287972 - N Engl J Med. 2001 Apr 5;344(14):1031-7
7542362 - Nature. 1995 Jul 20;376(6537):263-7
16838024 - Leukemia. 2006 Sep;20(9):1526-32
16304379 - Hematology Am Soc Hematol Educ Program. 2005;:188-94
22848414 - PLoS One. 2012;7(7):e40934
23138184 - Leukemia. 2013 Jun;27(6):1411-3
17496200 - Blood. 2007 Oct 1;110(7):2242-9
19801979 - Nat Genet. 2009 Nov;41(11):1207-15
8616716 - Nat Med. 1996 May;2(5):561-6
10360377 - Leukemia. 1999 Jun;13(6):884-90
21707583 - Br J Haematol. 2011 Sep;154(5):600-11
19805687 - J Clin Oncol. 2009 Nov 1;27(31):5175-81
12114423 - Clin Cancer Res. 2002 Jul;8(7):2217-24
18615627 - Cancer. 2008 Sep 1;113(5):985-94
24013638 - Nat Genet. 2013 Oct;45(10 ):1226-31
22897847 - Cancer Cell. 2012 Aug 14;22(2):153-66
15589172 - Immunity. 2004 Dec;21(6):843-51
9407116 - J Biol Chem. 1997 Dec 26;272(52):33260-70
11287973 - N Engl J Med. 2001 Apr 5;344(14):1038-42
11314042 - Oncogene. 2001 Mar 1;20(9):1052-62
20595523 - Blood. 2010 Jul 1;115(26):5428-9
21921043 - Blood. 2011 Nov 10;118(19):5218-26
12194988 - Annu Rev Genomics Hum Genet. 2002;3:179-98
19825449 - Hematol Oncol Clin North Am. 2009 Oct;23(5):991-1010, v
15155841 - Mol Pharmacol. 2004 Jun;65(6):1485-95
1712671 - Cell. 1991 Jul 12;66(1):161-71
8402896 - Cell. 1993 Oct 8;75(1):175-85
20385364 - Cancer Cell. 2010 Apr 13;17(4):400-11
15789066 - Leukemia. 2005 May;19(5):713-20
11929787 - Blood. 2002 Apr 15;99(8):2957-68
22134481 - Clin Cancer Res. 2011 Dec 1;17(23):7413-23
19047160 - Cancer Res. 2008 Dec 1;68(23):9809-16
23639321 - Lancet Oncol. 2013 May;14(6):e205-17
11940649 - Mol Cell Biol. 2002 May;22(9):2906-17
23526495 - Am J Hematol. 2013 Jun;88(6):534-5
23334668 - Nat Genet. 2013 Mar;45(3):242-52
18500345 - Nat Immunol. 2008 Jul;9(7):810-9
2005881 - Mol Cell Biol. 1991 Apr;11(4):1785-92
17405907 - Blood. 2007 Jul 15;110(2):727-34
17344859 - Nature. 2007 Apr 12;446(7137):758-64
21606506 - J Exp Med. 2011 Jun 6;208(6):1135-49
7553858 - Cell. 1995 Sep 22;82(6):981-8
11888894 - Cancer Res. 2002 Mar 1;62(5):1296-9
20072125 - Nature. 2010 Jan 28;463(7280):501-6
22496163 - Blood. 2012 May 31;119(22):5201-10
21730355 - Blood. 2011 Aug 25;118(8):2211-21
24291004 - Cancer Cell. 2013 Dec 9;24(6):766-76
23550147 - Cancer Discov. 2013 Apr;3(4):388-98
9442394 - Immunobiology. 1997 Dec;198(1-3):227-35
16638934 - Blood. 2006 Sep 1;108(5):1469-77
7923373 - Cell. 1994 Oct 7;79(1):143-56
4126434 - Nature. 1973 Jun 1;243(5405):290-3
2408149 - Science. 1990 Mar 2;247(4946):1079-82
19878872 - Cancer Cell. 2009 Nov 6;16(5):401-12
14576058 - Blood. 2004 Feb 15;103(4):1495-8
11735629 - Drugs. 2001;61(12):1775-1776
12783368 - Semin Hematol. 2003 Apr;40(2 Suppl 2):4-10
17638918 - Cancer Res. 2007 Jul 15;67(14):7045-53
2406902 - Science. 1990 Feb 16;247(4944):824-30
2725497 - Mol Cell Biol. 1989 Mar;9(3):1263-70
9876475 - Int J Cancer Suppl. 1998;11:35-9
18071309 - Oncogene. 2008 May 15;27(22):3194-200
17010674 - Cancer Cell. 2006 Oct;10(4):331-42
15509806 - Mol Cell Biol. 2004 Nov;24(22):10058-71
12714971 - Nature. 2003 May 15;423(6937):302-5
8246975 - Mol Cell Biol. 1993 Dec;13(12):7587-95
19589926 - Blood. 2009 Sep 3;114(10):2159-67
8001127 - Cell. 1994 Dec 2;79(5):901-12
9923679 - Nature. 1999 Jan 14;397(6715):164-8
17785208 - Cancer Cell. 2007 Sep;12 (3):280-92
8986714 - Immunity. 1996 Dec;5(6):537-49
15251980 - Blood. 2004 Nov 1;104(9):2940-2
12573439 - Curr Opin Genet Dev. 2003 Feb;13(1):77-83
18927431 - Blood. 2009 Apr 9;113(15):3397-405
11801308 - Cancer Genet Cytogenet. 2002 Jan 1;132(1):46-50
20486169 - Pediatr Blood Cancer. 2010 Jul 15;55(1):18-25
12970785 - Leukemia. 2003 Sep;17 (9):1845-50
16931177 - DNA Repair (Amst). 2006 Sep 8;5(9-10):1273-81
24779033 - Am J Hematol. 2014 Mar;89(3):282-7
21299459 - Leuk Lymphoma. 2011 Feb;52 Suppl 1:45-53
19684603 - Nat Genet. 2009 Sep;41(9):1001-5
21911423 - J Exp Med. 2011 Oct 24;208(11):2163-74
21183952 - Leukemia. 2011 Mar;25(3):463-72
12637609 - N Engl J Med. 2003 Mar 13;348(11):994-1004
22359103 - Int J Hematol. 2012 Apr;95(4):409-19
8642285 - J Exp Med. 1996 Mar 1;183(3):811-20
2179728 - Nature. 1990 Mar 15;344(6263):251-3
22898679 - Lancet Oncol. 2012 Sep;13(9):936-45
21856866 - Blood. 2011 Oct 13;118(15):4174-8
21263099 - J Clin Oncol. 2011 Mar 1;29(7):839-44
22829135 - Blood Cancer J. 2011 Apr;1(4):e14
23178377 - Exp Hematol. 2013 Mar;41(3):293-302.e1
10090949 - Blood. 1999 Apr 1;93(7):2380-5
9737691 - Leukemia. 1998 Sep;12(9):1417-21
22345515 - Genes Dev. 2012 Feb 15;26(4):344-9
19837270 - Cancer Genet Cytogenet. 2009 Nov;195(1):59-65
19602874 - Acta Haematol. 2009;122(1):6-10
9865697 - Cell. 1998 Dec 11;95(6):793-803
16822902 - Blood. 2006 Jul 15;108(2):711-7
23235717 - Leukemia. 2013 Apr;27(4):852-60
12444544 - Oncogene. 2002 Nov 21;21(53):8
References_xml – volume: 12
  start-page: 1417
  issue: 9
  year: 1998
  ident: B135
  article-title: Different patterns of homozygous p16INK4A and p15INK4B deletions in childhood acute lymphoblastic leukemias containing distinct E2A translocations
  publication-title: Leukemia
  doi: 10.1038/sj.leu.2401124
– year: 2013
  ident: B210
  article-title: Copy number genome alterations are associated with treatment response and outcome in relapsed childhood ETV6/RUNX1-positive acute lymphoblastic leukemia
  publication-title: Haematologica
  doi: 10.3324/haematol.2012.072470
– volume: 27
  start-page: 5175
  issue: 31
  year: 2009
  ident: B2
  article-title: Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children’s oncology group study
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2008.21.2514
– volume: 2
  start-page: 561
  issue: 5
  year: 1996
  ident: B11
  article-title: Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
  publication-title: Nat Med
  doi: 10.1038/nm0596-561
– volume: 26
  start-page: 224
  issue: 2
  year: 2007
  ident: B186
  article-title: STAT5 represses BCL6 expression by binding to a regulatory region frequently mutated in lymphomas
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1209775
– volume: 55
  year: 2010
  ident: B231
  article-title: Nilotinib combined with multi-agent chemotherapy for adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: final results of prospective multicenter Phase 2 study
  publication-title: Blood
– volume: 23
  start-page: 2242
  issue: 12
  year: 2009
  ident: B34
  article-title: Oligomerization inhibition, combined with allosteric inhibition, abrogates the transformation potential of T315I-positive BCR/ABL
  publication-title: Leukemia
  doi: 10.1038/leu.2009.194
– volume: 89
  start-page: 1399
  issue: 11
  year: 2004
  ident: B191
  article-title: Overexpression of Her2/neu is observed in one third of adult acute lymphoblastic leukemia patients and is associated with chemoresistance in these patients
  publication-title: Haematologica
– volume: 7
  start-page: e40934
  issue: 7
  year: 2012
  ident: B115
  article-title: IKAROS deletions dictate a unique gene expression signature in patients with adult B-cell acute lymphoblastic leukemia
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0040934
– volume: 1
  start-page: 346
  issue: 4
  year: 2010
  ident: B183
  article-title: Destabilization of Bcr-Abl/Jak2 network by a Jak2/Abl kinase inhibitor ON044580 overcomes drug resistance in blast crisis chronic myelogenous leukemia (CML)
  publication-title: Genes Cancer
  doi: 10.1177/1947601910372232
– volume: 16
  start-page: 401
  issue: 5
  year: 2009
  ident: B247
  article-title: AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance
  publication-title: Cancer Cell
  doi: 10.1016/j.ccr.2009.09.028
– volume: 27
  start-page: 503
  issue: 2
  year: 2013
  ident: B95
  article-title: Biclonal and biallelic deletions occur in 20% of B-ALL cases with IKZF1 mutations
  publication-title: Leukemia
  doi: 10.1038/leu.2012.204
– volume: 132
  start-page: 46
  issue: 1
  year: 2002
  ident: B173
  article-title: Philadelphia-positive acute lymphoblastic leukemia with multiple subclones including duplication of the Philadelphia chromosome and Abelson oncogene
  publication-title: Cancer Genet Cytogenet
  doi: 10.1016/S0165-4608(01)00507-6
– volume: 110
  start-page: 727
  issue: 2
  year: 2007
  ident: B169
  article-title: Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)
  publication-title: Blood
  doi: 10.1182/blood-2006-11-052373
– volume: 1
  start-page: e14
  issue: 4
  year: 2011
  ident: B214
  article-title: AMD3100 sensitizes acute lymphoblastic leukemia cells to chemotherapy in vivo
  publication-title: Blood Cancer J
  doi: 10.1038/bcj.2011.13
– volume: 52
  start-page: 140
  issue: 2–3
  year: 2014
  ident: B87
  article-title: High-resolution melting analyses for genetic variants in ARID5B and IKZF1 with childhood acute lymphoblastic leukemia susceptibility loci in Taiwan
  publication-title: Blood Cells Mol Dis
  doi: 10.1016/j.bcmd.2013.10.003
– volume: 118
  start-page: 5218
  issue: 19
  year: 2011
  ident: B203
  article-title: Integrated genomic analysis of relapsed childhood acute lymphoblastic leukemia reveals therapeutic strategies
  publication-title: Blood
  doi: 10.1182/blood-2011-04-345595
– volume: 22
  start-page: 168
  issue: 2
  year: 2010
  ident: B106
  article-title: STAT5 in B cell development and leukemia
  publication-title: Curr Opin Immunol
  doi: 10.1016/j.coi.2010.02.004
– volume: 354
  start-page: 2006
  issue: 19
  year: 2006
  ident: B234
  article-title: Altered bone and mineral metabolism in patients receiving imatinib mesylate
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa051140
– volume: 195
  start-page: 59
  issue: 1
  year: 2009
  ident: B138
  article-title: Homozygous deletion of CDKN2A (p16, p14) and CDKN2B (p15) genes is a poor prognostic factor in adult but not in childhood B-lineage acute lymphoblastic leukemia: a comparative deletion and hypermethylation study
  publication-title: Cancer Genet Cytogenet
  doi: 10.1016/j.cancergencyto.2009.06.013
– volume: 114
  start-page: 2159
  issue: 10
  year: 2009
  ident: B93
  article-title: Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell’Adulto Acute Leukemia Working Party (GIMEMA AL WP)
  publication-title: Blood
  doi: 10.1182/blood-2008-08-173963
– volume: 362
  start-page: 2251
  issue: 24
  year: 2010
  ident: B16
  article-title: Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa0912614
– volume: 56
  start-page: 3589
  issue: 15
  year: 1996
  ident: B67
  article-title: Activation of Src kinases p53/56lyn and p59hck by p210bcr/abl in myeloid cells
  publication-title: Cancer Res
– volume: 469
  start-page: 362
  issue: 7330
  year: 2011
  ident: B80
  article-title: Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells
  publication-title: Nature
  doi: 10.1038/nature09733
– volume: 103
  start-page: 6688
  issue: 17
  year: 2006
  ident: B141
  article-title: Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.0602030103
– volume: 29
  start-page: 217
  issue: 2
  year: 2008
  ident: B116
  article-title: E2A proteins promote development of lymphoid-primed multipotent progenitors
  publication-title: Immunity
  doi: 10.1016/j.immuni.2008.05.015
– start-page: 188
  year: 2005
  ident: B3
  article-title: Pathobiology of lymphoid and myeloid blast crisis and management issues
  publication-title: Hematology Am Soc Hematol Educ Program
  doi: 10.1182/asheducation-2005.1.188
– volume: 120
  start-page: 3510
  issue: 17
  year: 2012
  ident: B184
  article-title: Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia
  publication-title: Blood
  doi: 10.1182/blood-2012-03-415448
– volume: 123
  start-page: 3099
  issue: 7
  year: 2013
  ident: B151
  article-title: Integrated genetic and epigenetic analysis of childhood acute lymphoblastic leukemia
  publication-title: J Clin Invest
  doi: 10.1172/JCI66203
– volume: 13
  start-page: 7587
  issue: 12
  year: 1993
  ident: B27
  article-title: A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins
  publication-title: Mol Cell Biol
  doi: 10.1128/MCB.13.12.7587
– volume: 92
  start-page: 111
  issue: 2
  year: 2014
  ident: B54
  article-title: mTOR inhibitor rapamycin enhances anti-leukemia effect of imatinib on Ph+ acute lymphoblastic leukemia cells
  publication-title: Eur J Haematol
  doi: 10.1111/ejh.12202
– volume: 41
  start-page: 1006
  issue: 9
  year: 2009
  ident: B83
  article-title: Loci on 7p12.2, 10q21.2 and 14q11.2 are associated with risk of childhood acute lymphoblastic leukemia
  publication-title: Nat Genet
  doi: 10.1038/ng.430
– volume: 3
  start-page: 388
  issue: 4
  year: 2013
  ident: B249
  article-title: The basic principles of chimeric antigen receptor design
  publication-title: Cancer Discov
  doi: 10.1158/2159-8290.CD-12-0548
– volume: 300
  start-page: 765
  issue: 5894
  year: 1982
  ident: B21
  article-title: A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia
  publication-title: Nature
  doi: 10.1038/300765a0
– volume: 360
  start-page: 470
  issue: 5
  year: 2009
  ident: B99
  article-title: Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa0808253
– volume: 13
  start-page: 77
  issue: 1
  year: 2003
  ident: B133
  article-title: Tumor suppression by Ink4a-Arf: progress and puzzles
  publication-title: Curr Opin Genet Dev
  doi: 10.1016/S0959-437X(02)00013-8
– volume: 118
  start-page: 2211
  issue: 8
  year: 2011
  ident: B219
  article-title: Quantitative phosphoproteomics revealed interplay between Syk and Lyn in the resistance to nilotinib in chronic myeloid leukemia cells
  publication-title: Blood
  doi: 10.1182/blood-2010-10-313692
– volume: 27
  start-page: 1939
  issue: 9
  year: 2013
  ident: B232
  article-title: Nilotinib treatment-associated accelerated atherosclerosis: when is the risk justified?
  publication-title: Leukemia
  doi: 10.1038/leu.2013.112
– volume: 112
  start-page: 5190
  issue: 13
  year: 2008
  ident: B175
  article-title: BCR-ABL fusion transcript types and levels and their interaction with secondary genetic changes in determining the phenotype of Philadelphia chromosome-positive leukemias
  publication-title: Blood
  doi: 10.1182/blood-2008-04-148791
– volume: 103
  start-page: 3167
  issue: 8
  year: 2004
  ident: B40
  article-title: BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells
  publication-title: Blood
  doi: 10.1182/blood-2003-04-1271
– volume: 35
  start-page: 1534
  issue: 11
  year: 2011
  ident: B81
  article-title: Role of 657del5 NBN mutation and 7p12.2 (IKZF1), 9p21 (CDKN2A), 10q21.2 (ARID5B) and 14q11.2 (CEBPE) variation and risk of childhood ALL in the Polish population
  publication-title: Leuk Res
  doi: 10.1016/j.leukres.2011.07.034
– volume: 20
  start-page: 1526
  issue: 9
  year: 2006
  ident: B163
  article-title: Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: results of the GRAALL AFR09 study
  publication-title: Leukemia
  doi: 10.1038/sj.leu.2404320
– volume: 198
  start-page: 227
  issue: 1–3
  year: 1997
  ident: B124
  article-title: Essential functions of Pax-5 (BSAP) in pro-B cell development
  publication-title: Immunobiology
  doi: 10.1016/S0171-2985(97)80043-5
– volume: 360
  start-page: 524
  issue: 5
  year: 2009
  ident: B128
  article-title: Acute lymphoblastic leukemia – on the wings of IKAROS
  publication-title: N Engl J Med
  doi: 10.1056/NEJMe0809819
– volume: 41
  start-page: 293.e–302.e
  issue: 3
  year: 2013
  ident: B213
  article-title: Plerixafor (AMD3100) induces prolonged mobilization of acute lymphoblastic leukemia cells and increases the proportion of cycling cells in the blood in mice
  publication-title: Exp Hematol
  doi: 10.1016/j.exphem.2012.11.004
– volume: 271
  start-page: 31704
  issue: 49
  year: 1996
  ident: B50
  article-title: P210 and P190(BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members
  publication-title: J Biol Chem
  doi: 10.1074/jbc.271.49.31704
– volume: 30
  start-page: 4149
  issue: 17
  year: 2010
  ident: B114
  article-title: Ikaros and Aiolos inhibit pre-B-cell proliferation by directly suppressing c-Myc expression
  publication-title: Mol Cell Biol
  doi: 10.1128/MCB.00224-10
– volume: 52
  start-page: 45
  issue: Suppl 1
  year: 2011
  ident: B43
  article-title: Regulation of mammalian target of rapamycin and mitogen activated protein kinase pathways by BCR-ABL
  publication-title: Leuk Lymphoma
  doi: 10.3109/10428194.2010.546919
– volume: 154
  start-page: 600
  issue: 5
  year: 2011
  ident: B217
  article-title: Intermediate dose of imatinib in combination with chemotherapy followed by allogeneic stem cell transplantation improves early outcome in paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (ALL): results of the Spanish Cooperative Group SHOP studies ALL-94, ALL-99 and ALL-2005
  publication-title: Br J Haematol
  doi: 10.1111/j.1365-2141.2011.08783.x
– volume: 103
  start-page: 4396
  issue: 12
  year: 2004
  ident: B157
  article-title: Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate
  publication-title: Blood
  doi: 10.1182/blood-2003-08-2958
– volume: 463
  start-page: 501
  issue: 7280
  year: 2010
  ident: B35
  article-title: Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors
  publication-title: Nature
  doi: 10.1038/nature08675
– volume: 27
  start-page: 852
  issue: 4
  year: 2013
  ident: B197
  article-title: Cell of origin determines clinically relevant subtypes of MLL-rearranged AML
  publication-title: Leukemia
  doi: 10.1038/leu.2012.363
– volume: 27
  start-page: 469
  issue: 3
  year: 2009
  ident: B245
  article-title: Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2008.19.8853
– volume: 18
  start-page: 401
  issue: 3
  year: 2004
  ident: B177
  article-title: P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate
  publication-title: Leukemia
  doi: 10.1038/sj.leu.2403257
– volume: 108
  start-page: 711
  issue: 2
  year: 2006
  ident: B204
  article-title: Biologic pathways associated with relapse in childhood acute lymphoblastic leukemia: a Children’s Oncology Group study
  publication-title: Blood
  doi: 10.1182/blood-2006-02-002824
– volume: 31
  start-page: 2460
  issue: 19
  year: 2013
  ident: B224
  article-title: Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2012.46.8280
– volume: 118
  start-page: 3080
  issue: 11
  year: 2011
  ident: B119
  article-title: Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children’s Oncology Group
  publication-title: Blood
  doi: 10.1182/blood-2011-03-341412
– volume: 21
  start-page: 843
  issue: 6
  year: 2004
  ident: B131
  article-title: Enhanced self-renewal of hematopoietic stem cells mediated by the polycomb gene product Bmi-1
  publication-title: Immunity
  doi: 10.1016/j.immuni.2004.11.004
– volume: 95
  start-page: 409
  issue: 4
  year: 2012
  ident: B229
  article-title: Efficacy and safety of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL: a 36-month analysis of a phase I and II study
  publication-title: Int J Hematol
  doi: 10.1007/s12185-012-1026-9
– volume: 21
  start-page: 8075
  issue: 53
  year: 2002
  ident: B69
  article-title: Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1206008
– volume: 102
  start-page: 659
  issue: 2
  year: 2003
  ident: B170
  article-title: Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia
  publication-title: Blood
  doi: 10.1182/blood-2002-06-1756
– volume: 4
  start-page: 331
  issue: 5
  year: 2004
  ident: B209
  article-title: Polymorphisms in genes involved in the corticosteroid response and the outcome of childhood acute lymphoblastic leukemia
  publication-title: Am J Pharmacogenomics
  doi: 10.2165/00129785-200404050-00006
– volume: 189
  start-page: 1399
  issue: 9
  year: 1999
  ident: B22
  article-title: The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity
  publication-title: J Exp Med
  doi: 10.1084/jem.189.9.1399
– volume: 29
  start-page: 839
  issue: 7
  year: 2011
  ident: B225
  article-title: Pediatric phase I trial and pharmacokinetic study of dasatinib: a report from the Children’s Oncology Group Phase I Consortium
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2010.30.7231
– volume: 16
  start-page: 137
  issue: 4
  year: 1998
  ident: B108
  article-title: Lack of natural killer cell precursors in fetal liver of Ikaros knockout mutant mice
  publication-title: Nat Immun
  doi: 10.1159/000069438
– volume: 79
  start-page: 901
  issue: 5
  year: 1994
  ident: B123
  article-title: Complete block of early B cell differentiation and altered patterning of the posterior midbrain in mice lacking Pax5/BSAP
  publication-title: Cell
  doi: 10.1016/0092-8674(94)90079-5
– volume: 40
  start-page: 4
  issue: 2 Suppl 2
  year: 2003
  ident: B37
  article-title: Molecular mechanisms of transformation by the BCR-ABL oncogene
  publication-title: Semin Hematol
  doi: 10.1053/shem.2003.50034
– volume: 77
  start-page: 324
  issue: 2
  year: 1991
  ident: B24
  article-title: Consistent involvement of the bcr gene by 9;22 breakpoints in pediatric acute leukemias
  publication-title: Blood
  doi: 10.1182/blood.V77.2.324.324
– volume: 99
  start-page: 2957
  issue: 8
  year: 2002
  ident: B28
  article-title: The coiled-coil domain and Tyr177 of bcr are required to induce a murine chronic myelogenous leukemia-like disease by bcr/abl
  publication-title: Blood
  doi: 10.1182/blood.V99.8.2957
– volume: 21
  start-page: 5766
  issue: 21
  year: 2002
  ident: B65
  article-title: The Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid leukemia cells
  publication-title: EMBO J
  doi: 10.1093/emboj/cdf562
– volume: 86
  start-page: 4603
  issue: 12
  year: 1995
  ident: B79
  article-title: BCR/ABL P210 and P190 cause distinct leukemia in transgenic mice
  publication-title: Blood
  doi: 10.1182/blood.V86.12.4603.bloodjournal86124603
– volume: 446
  start-page: 758
  issue: 7137
  year: 2007
  ident: B118
  article-title: Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia
  publication-title: Nature
  doi: 10.1038/nature05690
– volume: 95
  start-page: 1683
  issue: 10
  year: 2010
  ident: B120
  article-title: The PAX5 gene is frequently rearranged in BCR-ABL1-positive acute lymphoblastic leukemia but is not associated with outcome. A report on behalf of the GIMEMA Acute Leukemia Working Party
  publication-title: Haematologica
  doi: 10.3324/haematol.2009.020792
– volume: 66
  start-page: 161
  issue: 1
  year: 1991
  ident: B32
  article-title: BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner
  publication-title: Cell
  doi: 10.1016/0092-8674(91)90148-R
– volume: 118
  start-page: 3038
  issue: 9
  year: 2008
  ident: B41
  article-title: Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells
  publication-title: J Clin Invest
  doi: 10.1172/JCI33337
– volume: 67
  start-page: 7045
  issue: 14
  year: 2007
  ident: B39
  article-title: BCR-tyrosine 177 plays an essential role in Ras and Akt activation and in human hematopoietic progenitor transformation in chronic myelogenous leukemia
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-06-4312
– volume: 449
  start-page: 473
  issue: 7161
  year: 2007
  ident: B127
  article-title: Conversion of mature B cells into T cells by dedifferentiation to uncommitted progenitors
  publication-title: Nature
  doi: 10.1038/nature06159
– volume: 113
  start-page: 3397
  issue: 15
  year: 2009
  ident: B250
  article-title: A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo
  publication-title: Blood
  doi: 10.1182/blood-2008-07-168773
– volume: 45
  start-page: 1226
  issue: 10
  year: 2013
  ident: B88
  article-title: A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia
  publication-title: Nat Genet
  doi: 10.1038/ng.2754
– volume: 112
  start-page: 1005
  issue: 4
  year: 2008
  ident: B218
  article-title: Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia
  publication-title: Blood
  doi: 10.1182/blood-2008-02-140665
– volume: 12
  start-page: 280
  issue: 3
  year: 2007
  ident: B185
  article-title: A signaling pathway mediating downregulation of BCL6 in germinal center B cells is blocked by BCL6 gene alterations in B cell lymphoma
  publication-title: Cancer Cell
  doi: 10.1016/j.ccr.2007.08.011
– volume: 397
  start-page: 164
  issue: 6715
  year: 1999
  ident: B132
  article-title: The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus
  publication-title: Nature
  doi: 10.1038/16476
– volume: 115
  start-page: 5428
  issue: 26
  year: 2010
  ident: B168
  article-title: Uncommon BCR-ABL kinase domain mutations in kinase inhibitor-resistant chronic myelogenous leukemia and Ph+ acute lymphoblastic leukemia show high rates of regression, suggesting weak selective effects
  publication-title: Blood
  doi: 10.1182/blood-2009-11-252155
– volume: 344
  start-page: 1038
  issue: 14
  year: 2001
  ident: B13
  article-title: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome
  publication-title: N Engl J Med
  doi: 10.1056/NEJM200104053441402
– volume: 11
  start-page: 1785
  issue: 4
  year: 1991
  ident: B31
  article-title: BCR first exon sequences specifically activate the BCR/ABL tyrosine kinase oncogene of Philadelphia chromosome-positive human leukemias
  publication-title: Mol Cell Biol
  doi: 10.1128/MCB.11.4.1785
– volume: 65
  start-page: 4500
  issue: 11
  year: 2005
  ident: B53
  article-title: In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-05-0259
– volume: 43
  start-page: 107
  issue: 2
  year: 2009
  ident: B241
  article-title: Allo-hematopoietic cell transplantation for Ph chromosome-positive ALL: impact of imatinib on relapse and survival
  publication-title: Bone Marrow Transplant
  doi: 10.1038/bmt.2008.296
– volume: 369
  start-page: 1783
  issue: 19
  year: 2013
  ident: B18
  article-title: A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1306494
– volume: 65
  start-page: 1485
  issue: 6
  year: 2004
  ident: B112
  article-title: High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter
  publication-title: Mol Pharmacol
  doi: 10.1124/mol.65.6.1485
– volume: 112
  start-page: 3847
  issue: 9
  year: 2008
  ident: B97
  article-title: Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new mechanism of resistance
  publication-title: Blood
  doi: 10.1182/blood-2007-09-112631
– volume: 19
  start-page: 1509
  issue: 9
  year: 2005
  ident: B158
  article-title: Clinical effect of imatinib added to intensive combination chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia
  publication-title: Leukemia
  doi: 10.1038/sj.leu.2403886
– volume: 44
  start-page: 169
  issue: 3
  year: 2009
  ident: B240
  article-title: Imatinib use either pre- or post-allogeneic hematopoietic cell transplantation (allo-HCT) does not increase cardiac toxicity in chronic myelogenous leukemia patients
  publication-title: Bone Marrow Transplant
  doi: 10.1038/bmt.2008.441
– volume: 25
  start-page: 85
  year: 1960
  ident: B19
  article-title: Chromosome studies on normal and leukemic human leukocytes
  publication-title: J Natl Cancer Inst
– volume: 93
  start-page: 2380
  issue: 7
  year: 1999
  ident: B147
  article-title: Acquisition of p16(INK4A) and p15(INK4B) gene abnormalities between initial diagnosis and relapse in children with acute lymphoblastic leukemia
  publication-title: Blood
  doi: 10.1182/blood.V93.7.2380
– volume: 9
  start-page: 955
  issue: 6
  year: 1995
  ident: B199
  article-title: p53 gene inactivation in acute lymphoblastic leukemia of B cell lineage associates with chromosomal breakpoints at 11q23 and 8q24
  publication-title: Leukemia
– volume: 111
  start-page: 3821
  issue: 7
  year: 2008
  ident: B72
  article-title: Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells
  publication-title: Blood
  doi: 10.1182/blood-2007-08-109330
– volume: 88
  start-page: 534
  issue: 6
  year: 2013
  ident: B233
  article-title: Nilotinib treatment-associated cerebrovascular disease and stroke
  publication-title: Am J Hematol
  doi: 10.1002/ajh.23442
– volume: 10
  start-page: 1724
  issue: 11
  year: 1996
  ident: B48
  article-title: BCR/abl leads to the constitutive activation of Stat proteins, and shares an epitope with tyrosine phosphorylated Stats
  publication-title: Leukemia
– volume: 19
  start-page: 713
  issue: 5
  year: 2005
  ident: B144
  article-title: Genetic heterogeneity of BCR/ABL+ adult B-cell precursor acute lymphoblastic leukemia: impact on the clinical, biological and immunophenotypical disease characteristics
  publication-title: Leukemia
  doi: 10.1038/sj.leu.2403714
– volume: 104
  start-page: 2940
  issue: 9
  year: 2004
  ident: B178
  article-title: Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump
  publication-title: Blood
  doi: 10.1182/blood-2004-04-1398
– volume: 22
  start-page: 2906
  issue: 9
  year: 2002
  ident: B153
  article-title: DNA methyltransferase deficiency modifies cancer susceptibility in mice lacking DNA mismatch repair
  publication-title: Mol Cell Biol
  doi: 10.1128/MCB.22.9.2906-2917.2002
– volume: 22
  start-page: 1411
  issue: 11
  year: 2008
  ident: B137
  article-title: Failure of CDKN2A/B (INK4A/B-ARF)-mediated tumor suppression and resistance to targeted therapy in acute lymphoblastic leukemia induced by BCR-ABL
  publication-title: Genes Dev
  doi: 10.1101/gad.1673908
– volume: 30
  start-page: 493
  issue: 4
  year: 2009
  ident: B105
  article-title: Genome-wide lineage-specific transcriptional networks underscore Ikaros-dependent lymphoid priming in hematopoietic stem cells
  publication-title: Immunity
  doi: 10.1016/j.immuni.2009.01.014
– volume: 79
  start-page: 143
  issue: 1
  year: 1994
  ident: B98
  article-title: The Ikaros gene is required for the development of all lymphoid lineages
  publication-title: Cell
  doi: 10.1016/0092-8674(94)90407-3
– volume: 4
  start-page: 104
  issue: 2
  year: 2003
  ident: B96
  article-title: Overexpression of dominant-negative Ikaros 6 protein is restricted to a subset of B common adult acute lymphoblastic leukemias that express high levels of the CD34 antigen
  publication-title: Hematol J
  doi: 10.1038/sj.thj.6200235
– volume: 20
  start-page: 1052
  issue: 9
  year: 2001
  ident: B60
  article-title: The C-terminal SH3 domain of the adapter protein Grb2 binds with high affinity to sequences in Gab1 and SLP-76 which lack the SH3-typical P-x-x-P core motif
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1204202
– volume: 14
  start-page: 299
  issue: 5
  year: 2012
  ident: B57
  article-title: Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies
  publication-title: Paediatr Drugs
  doi: 10.2165/11594740-000000000-00000
– volume: 471
  start-page: 235
  issue: 7337
  year: 2011
  ident: B211
  article-title: CREBBP mutations in relapsed acute lymphoblastic leukaemia
  publication-title: Nature
  doi: 10.1038/nature09727
– volume: 362
  start-page: 2260
  issue: 24
  year: 2010
  ident: B15
  article-title: Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1002315
– volume: 62
  start-page: 1296
  issue: 5
  year: 2002
  ident: B152
  article-title: Complete genetic suppression of polyp formation and reduction of CpG-island hypermethylation in Apc(Min/+) Dnmt1-hypomorphic Mice
  publication-title: Cancer Res
– year: 2014
  ident: B216
  article-title: Long term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children’s Oncology Group Study AALL0031
  publication-title: Leukemia
  doi: 10.1038/leu.2014.30
– volume: 11
  start-page: 4710
  issue: 9
  year: 1991
  ident: B7
  article-title: Differences in oncogenic potency but not target cell specificity distinguish the two forms of the BCR/ABL oncogene
  publication-title: Mol Cell Biol
  doi: 10.1128/MCB.11.9.4710
– volume: 99
  start-page: 602
  issue: 2
  year: 2002
  ident: B104
  article-title: Multiple hematopoietic defects and delayed globin switching in Ikaros null mice
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.022412699
– volume: 119
  start-page: 5201
  issue: 22
  year: 2012
  ident: B148
  article-title: Epigenetic reprogramming reverses the relapse-specific gene expression signature and restores chemosensitivity in childhood B-lymphoblastic leukemia
  publication-title: Blood
  doi: 10.1182/blood-2012-01-401687
– volume: 56
  start-page: 671
  issue: 4
  year: 2011
  ident: B236
  article-title: Acquired growth hormone deficiency in a girl with chronic myelogenous leukemia treated with tyrosine kinase inhibitor therapy
  publication-title: Pediatr Blood Cancer
  doi: 10.1002/pbc.22945
– volume: 5
  start-page: 1273
  issue: 9–10
  year: 2006
  ident: B140
  article-title: Molecular processes of chromosome 9p21 deletions causing inactivation of the p16 tumor suppressor gene in human cancer: deduction from structural analysis of breakpoints for deletions
  publication-title: DNA Repair
  doi: 10.1016/j.dnarep.2006.05.021
– volume: 27
  start-page: 1411
  issue: 6
  year: 2013
  ident: B228
  article-title: Phase II study of nilotinib in patients with relapsed or refractory Philadelphia chromosome – positive acute lymphoblastic leukemia
  publication-title: Leukemia
  doi: 10.1038/leu.2012.324
– volume: 41
  start-page: 1207
  issue: 11
  year: 2009
  ident: B155
  article-title: DNA methylation protects hematopoietic stem cell multipotency from myeloerythroid restriction
  publication-title: Nat Genet
  doi: 10.1038/ng.463
– volume: 116
  start-page: 2070
  issue: 12
  year: 2010
  ident: B222
  article-title: First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia
  publication-title: Blood
  doi: 10.1182/blood-2009-12-261586
– volume: 5
  start-page: 29
  year: 2012
  ident: B244
  article-title: Administration of imatinib after allogeneic hematopoietic stem cell transplantation may improve disease-free survival for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
  publication-title: J Hematol Oncol
  doi: 10.1186/1756-8722-5-29
– volume: 75
  start-page: 2080
  issue: 11
  year: 2008
  ident: B248
  article-title: The cytotoxicity of a Grb2-SH3 inhibitor in Bcr-Abl positive K562 cells
  publication-title: Biochem Pharmacol
  doi: 10.1016/j.bcp.2007.12.021
– volume: 100
  start-page: 926
  issue: 13
  year: 2008
  ident: B181
  article-title: Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase
  publication-title: J Natl Cancer Inst
  doi: 10.1093/jnci/djn188
– volume: 304
  start-page: 2706
  issue: 24
  year: 2010
  ident: B195
  article-title: Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia
  publication-title: JAMA
  doi: 10.1001/jama.2010.1862
– volume: 208
  start-page: 1135
  issue: 6
  year: 2011
  ident: B130
  article-title: Ebf1 or Pax5 haploinsufficiency synergizes with STAT5 activation to initiate acute lymphoblastic leukemia
  publication-title: J Exp Med
  doi: 10.1084/jem.20101947
– volume: 9
  start-page: 1263
  issue: 3
  year: 1989
  ident: B78
  article-title: The BCR-ABL oncogene transforms Rat-1 cells and cooperates with v-myc
  publication-title: Mol Cell Biol
  doi: 10.1128/MCB.9.3.1263
– volume: 101
  start-page: 690
  issue: 2
  year: 2003
  ident: B182
  article-title: BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571
  publication-title: Blood
  doi: 10.1182/blood.V101.2.690
– volume: 27
  start-page: 1254
  issue: 6
  year: 2013
  ident: B243
  article-title: Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia
  publication-title: Leukemia
  doi: 10.1038/leu.2012.352
– volume: 24
  start-page: 10058
  issue: 22
  year: 2004
  ident: B187
  article-title: FoxO3a and BCR-ABL regulate cyclin D2 transcription through a STAT5/BCL6-dependent mechanism
  publication-title: Mol Cell Biol
  doi: 10.1128/MCB.24.22.10058-10071.2004
– volume: 285
  start-page: 21446
  issue: 28
  year: 2010
  ident: B73
  article-title: Expression of a Src family kinase in chronic myelogenous leukemia cells induces resistance to imatinib in a kinase-dependent manner
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M109.090043
– volume: 43
  start-page: 126
  issue: 2
  year: 2006
  ident: B6
  article-title: Management of acute lymphoblastic leukemia in older patients
  publication-title: Semin Hematol
  doi: 10.1053/j.seminhematol.2006.01.007
– volume: 75
  start-page: 175
  issue: 1
  year: 1993
  ident: B61
  article-title: BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein
  publication-title: Cell
  doi: 10.1016/0092-8674(93)90689-N
– volume: 85
  start-page: 164
  issue: 3
  year: 2010
  ident: B221
  article-title: Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: results from a phase 3 study
  publication-title: Am J Hematol
  doi: 10.1002/ajh.21615
– volume: 247
  start-page: 824
  issue: 4944
  year: 1990
  ident: B8
  article-title: Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome
  publication-title: Science
  doi: 10.1126/science.2406902
– volume: 27
  start-page: 7055
  issue: 56
  year: 2008
  ident: B71
  article-title: An inhibitor-resistant mutant of Hck protects CML cells against the antiproliferative and apoptotic effects of the broad-spectrum Src family kinase inhibitor A-419259
  publication-title: Oncogene
  doi: 10.1038/onc.2008.330
– volume: 107
  start-page: 4898
  issue: 12
  year: 2006
  ident: B46
  article-title: Clarifying the role of Stat5 in lymphoid development and Abelson-induced transformation
  publication-title: Blood
  doi: 10.1182/blood-2005-09-3596
– volume: 24
  start-page: 1258
  issue: 7
  year: 2010
  ident: B192
  article-title: IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL
  publication-title: Leukemia
  doi: 10.1038/leu.2010.87
– volume: 24
  start-page: 766
  issue: 6
  year: 2013
  ident: B55
  article-title: Direct reversal of glucocorticoid resistance by AKT inhibition in acute lymphoblastic leukemia
  publication-title: Cancer Cell
  doi: 10.1016/j.ccr.2013.10.022
– volume: 275
  start-page: 18581
  issue: 24
  year: 2000
  ident: B68
  article-title: Transformation of myeloid leukemia cells to cytokine independence by Bcr-Abl is suppressed by kinase-defective Hck
  publication-title: J Biol Chem
  doi: 10.1074/jbc.C000126200
– volume: 13
  start-page: 884
  issue: 6
  year: 1999
  ident: B143
  article-title: p16/MTS1/INK4A gene is frequently inactivated by hypermethylation in childhood acute lymphoblastic leukemia with 11q23 translocation
  publication-title: Leukemia
  doi: 10.1038/sj.leu.2401437
– volume: 344
  start-page: 251
  issue: 6263
  year: 1990
  ident: B9
  article-title: Acute leukaemia in bcr/abl transgenic mice
  publication-title: Nature
  doi: 10.1038/344251a0
– volume: 61
  start-page: 1775
  issue: 12
  year: 2001
  ident: B161
  article-title: Imatinib: a viewpoint by Brian J. Druker
  publication-title: Drugs
  doi: 10.2165/00003495-200161120-00009
– volume: 85
  start-page: 1219
  issue: 9
  year: 2013
  ident: B205
  article-title: Molecular aspects of cancer cell resistance to chemotherapy
  publication-title: Biochem Pharmacol
  doi: 10.1016/j.bcp.2013.02.017
– volume: 105
  start-page: 733
  issue: 10
  year: 2013
  ident: B90
  article-title: Novel susceptibility variants at 10p12.31-12.2 for childhood acute lymphoblastic leukemia in ethnically diverse populations
  publication-title: J Natl Cancer Inst
  doi: 10.1093/jnci/djt042
– volume: 247
  start-page: 1079
  issue: 4946
  year: 1990
  ident: B10
  article-title: Tyrosine kinase activity and transformation potency of bcr-abl oncogene products
  publication-title: Science
  doi: 10.1126/science.2408149
– volume: 98
  start-page: 1081
  issue: 7
  year: 2013
  ident: B136
  article-title: Genes commonly deleted in childhood B-cell precursor acute lymphoblastic leukemia: association with cytogenetics and clinical features
  publication-title: Haematologica
  doi: 10.3324/haematol.2013.085175
– volume: 99
  start-page: 3472
  issue: 9
  year: 2002
  ident: B166
  article-title: High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance
  publication-title: Blood
  doi: 10.1182/blood.V99.9.3472
– volume: 2012
  start-page: 122
  year: 2012
  ident: B1
  article-title: Is going for cure in chronic myeloid leukemia possible and justifiable?
  publication-title: Hematology Am Soc Hematol Educ Program
  doi: 10.1182/asheducation-2012.1.122
– volume: 423
  start-page: 302
  issue: 6937
  year: 2003
  ident: B134
  article-title: Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells
  publication-title: Nature
  doi: 10.1038/nature01587
– volume: 17
  start-page: 7413
  issue: 23
  year: 2011
  ident: B149
  article-title: CDKN2A/B alterations impair prognosis in adult BCR-ABL1-positive acute lymphoblastic leukemia patients
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-11-1227
– volume: 103
  start-page: 16870
  issue: 45
  year: 2006
  ident: B74
  article-title: Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.0606509103
– volume: 101
  start-page: 664
  issue: 2
  year: 2003
  ident: B70
  article-title: Dual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate-resistant Bcr-Abl kinases
  publication-title: Blood
  doi: 10.1182/blood-2002-01-0288
– volume: 25
  start-page: 463
  issue: 3
  year: 2011
  ident: B52
  article-title: Janus kinase 2 regulates Bcr-Abl signaling in chronic myeloid leukemia
  publication-title: Leukemia
  doi: 10.1038/leu.2010.287
– volume: 22
  start-page: 177
  issue: 2
  year: 2010
  ident: B107
  article-title: From hematopoietic progenitors to B cells: mechanisms of lineage restriction and commitment
  publication-title: Curr Opin Immunol
  doi: 10.1016/j.coi.2010.02.003
– volume: 28
  start-page: 4755
  issue: 31
  year: 2010
  ident: B4
  article-title: Clinical outcome of children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2010.30.1325
– volume: 120
  start-page: 137
  year: 2012
  ident: B226
  article-title: Continuous dose dasatinib is safe and feasible in combination with intensive chemotherapy in pediatric Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL): Children’s Oncology Group (COG) Trial AALL0622
  publication-title: Blood
  doi: 10.1182/blood.V120.21.137.137
– volume: 109
  start-page: 2791
  issue: 7
  year: 2007
  ident: B239
  article-title: Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia
  publication-title: Blood
  doi: 10.1182/blood-2006-04-019836
– volume: 322
  start-page: 1377
  issue: 5906
  year: 2008
  ident: B193
  article-title: Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia
  publication-title: Science
  doi: 10.1126/science.1164266
– volume: 119
  start-page: 3512
  issue: 15
  year: 2012
  ident: B117
  article-title: Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children’s Oncology Group study
  publication-title: Blood
  doi: 10.1182/blood-2011-11-394221
– volume: 3
  start-page: 436
  issue: 5–6
  year: 2012
  ident: B26
  article-title: Structure, regulation, signaling, and targeting of abl kinases in cancer
  publication-title: Genes Cancer
  doi: 10.1177/1947601912458584
– volume: 17
  start-page: 1845
  issue: 9
  year: 2003
  ident: B142
  article-title: Concurrent methylation of multiple genes in childhood ALL: correlation with phenotype and molecular subgroup
  publication-title: Leukemia
  doi: 10.1038/sj.leu.2403060
– volume: 115
  start-page: 1765
  issue: 9
  year: 2010
  ident: B82
  article-title: Verification of the susceptibility loci on 7p12.2, 10q21.2, and 14q11.2 in precursor B-cell acute lymphoblastic leukemia of childhood
  publication-title: Blood
  doi: 10.1182/blood-2009-09-241513
– volume: 116
  start-page: 885
  year: 2010
  ident: B230
  article-title: A pilot study of the combination of nilotinib and hyper-CVAD for Philadelphia chromosome positive acute lymphocytic leukemia and lymphoid blast crisis chronic myelogenous leukemia
  publication-title: Blood
  doi: 10.1182/blood.V116.21.2144.2144
– volume: 8
  start-page: 137
  issue: 1
  year: 1989
  ident: B25
  article-title: Deletion of an N-terminal regulatory domain of the c-abl tyrosine kinase activates its oncogenic potential
  publication-title: EMBO J
  doi: 10.1002/j.1460-2075.1989.tb03358.x
– volume: 105
  start-page: 1348
  issue: 3
  year: 2005
  ident: B238
  article-title: Final adult height of patients who received hematopoietic cell transplantation in childhood
  publication-title: Blood
  doi: 10.1182/blood-2004-07-2528
– volume: 25
  start-page: 305
  issue: 2
  year: 2011
  ident: B45
  article-title: Inhibition of Grb2 expression demonstrates an important role in BCR-ABL-mediated MAPK activation and transformation of primary human hematopoietic cells
  publication-title: Leukemia
  doi: 10.1038/leu.2010.257
– volume: 9
  start-page: 810
  issue: 7
  year: 2008
  ident: B198
  article-title: The transcription factor Erg is essential for definitive hematopoiesis and the function of adult hematopoietic stem cells
  publication-title: Nat Immunol
  doi: 10.1038/ni.1617
– volume: 9
  start-page: 1866
  issue: 5
  year: 1989
  ident: B23
  article-title: Alternative forms of the BCR-ABL oncogene have quantitatively different potencies for stimulation of immature lymphoid cells
  publication-title: Mol Cell Biol
  doi: 10.1128/MCB.9.5.1866
– volume: 12
  start-page: 7374
  issue: 24
  year: 2006
  ident: B167
  article-title: Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-06-1516
– volume: 348
  start-page: 994
  issue: 11
  year: 2003
  ident: B14
  article-title: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa022457
– volume: 17
  start-page: 1298
  issue: 10
  year: 2011
  ident: B207
  article-title: Somatic deletions of genes regulating MSH2 protein stability cause DNA mismatch repair deficiency and drug resistance in human leukemia cells
  publication-title: Nat Med
  doi: 10.1038/nm.2430
– volume: 473
  start-page: 384
  issue: 7347
  year: 2011
  ident: B188
  article-title: BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition
  publication-title: Nature
  doi: 10.1038/nature09883
– volume: 17
  start-page: 283
  issue: 2
  year: 2003
  ident: B66
  article-title: The interaction of the Bcr-Abl tyrosine kinase with the Src kinase Hck is mediated by multiple binding domains
  publication-title: Leukemia
  doi: 10.1038/sj.leu.2402778
– volume: 59
  start-page: 988
  year: 2012
  ident: B227
  article-title: Outstanding early responses with dasatinib and intensive chemotherapy in pediatric Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL): Children’s Oncology Group (COG) trial AALL0622
  publication-title: Pediatr Blood Cancer
– volume: 108
  start-page: 1469
  issue: 5
  year: 2006
  ident: B160
  article-title: Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)
  publication-title: Blood
  doi: 10.1182/blood-2005-11-4386
– volume: 4
  start-page: 747
  issue: 7
  year: 2005
  ident: B176
  article-title: Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps
  publication-title: Cancer Biol Ther
  doi: 10.4161/cbt.4.7.1826
– volume: 98
  start-page: 1773
  issue: 6
  year: 2001
  ident: B59
  article-title: Chronic myelogenous leukemia blast cell proliferation is inhibited by peptides that disrupt Grb2-SoS complexes
  publication-title: Blood
  doi: 10.1182/blood.V98.6.1773
– volume: 2
  start-page: 108
  issue: 6
  year: 2011
  ident: B110
  article-title: Role of Ikaros in T-cell acute lymphoblastic leukemia
  publication-title: World J Biol Chem
  doi: 10.4331/wjbc.v2.i6.108
– volume: 31
  start-page: e413
  issue: 25
  year: 2013
  ident: B77
  article-title: Tyrosine kinase inhibitor therapy induces remission in a patient with refractory EBF1-PDGFRB-positive acute lymphoblastic leukemia
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2012.47.6770
– volume: 121
  start-page: 4821
  issue: 24
  year: 2013
  ident: B212
  article-title: Adhesion to osteopontin in the bone marrow niche regulates lymphoblastic leukemia cell dormancy
  publication-title: Blood
  doi: 10.1182/blood-2012-12-475483
– volume: 37
  start-page: 936
  issue: 8
  year: 2013
  ident: B85
  article-title: ARID5B and IKZF1 variants, selected demographic factors, and childhood acute lymphoblastic leukemia: a report from the Children’s Oncology Group
  publication-title: Leuk Res
  doi: 10.1016/j.leukres.2013.04.022
– volume: 66
  start-page: 11314
  issue: 23
  year: 2006
  ident: B17
  article-title: In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-06-1199
– volume: 41
  start-page: 1001
  issue: 9
  year: 2009
  ident: B84
  article-title: Germline genomic variants associated with childhood acute lymphoblastic leukemia
  publication-title: Nat Genet
  doi: 10.1038/ng.432
– volume: 453
  start-page: 110
  issue: 7191
  year: 2008
  ident: B92
  article-title: BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros
  publication-title: Nature
  doi: 10.1038/nature06866
– volume: 71
  start-page: 291
  issue: 4
  year: 2002
  ident: B174
  article-title: Additional chromosomal abnormalities and variability of BCR breakpoints in Philadelphia chromosome/BCR-ABL-positive acute lymphoblastic leukemia in Taiwan
  publication-title: Am J Hematol
  doi: 10.1002/ajh.10227
– volume: 122
  start-page: 2744
  issue: 12
  year: 2008
  ident: B33
  article-title: Targeting of the N-terminal coiled coil oligomerization interface by a helix-2 peptide inhibits unmutated and imatinib-resistant BCR/ABL
  publication-title: Int J Cancer
  doi: 10.1002/ijc.23467
– volume: 23
  start-page: 991
  issue: 5
  year: 2009
  ident: B5
  article-title: Cytogenetics and molecular genetics of acute lymphoblastic leukemia
  publication-title: Hematol Oncol Clin North Am
  doi: 10.1016/j.hoc.2009.07.001
– volume: 29
  start-page: 3185
  issue: 23
  year: 2011
  ident: B201
  article-title: Mutations and deletions of the TP53 gene predict nonresponse to treatment and poor outcome in first relapse of childhood acute lymphoblastic leukemia
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2011.34.8144
– volume: 17
  start-page: 400
  issue: 4
  year: 2010
  ident: B251
  article-title: A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo
  publication-title: Cancer Cell
  doi: 10.1016/j.ccr.2009.12.050
– volume: 157
  start-page: 507
  issue: 4
  year: 2012
  ident: B38
  article-title: Imatinib resistant BCR-ABL1 mutations at relapse in children with Ph+ ALL: a Children’s Oncology Group (COG) study
  publication-title: Br J Haematol
  doi: 10.1111/j.1365-2141.2012.09039.x
– volume: 85
  start-page: 2013
  issue: 8
  year: 1995
  ident: B139
  article-title: Homozygous deletions of the p16 tumor-suppressor gene are associated with lymphoid transformation of chronic myeloid leukemia
  publication-title: Blood
  doi: 10.1182/blood.V85.8.2013.bloodjournal8582013
– volume: 272
  start-page: 33260
  issue: 52
  year: 1997
  ident: B64
  article-title: The Src family kinase Hck interacts with Bcr-Abl by a kinase-independent mechanism and phosphorylates the Grb2-binding site of Bcr
  publication-title: J Biol Chem
  doi: 10.1074/jbc.272.52.33260
– volume: 17
  start-page: 1086
  issue: 9
  year: 2011
  ident: B194
  article-title: Stem cell gene expression programs influence clinical outcome in human leukemia
  publication-title: Nat Med
  doi: 10.1038/nm.2415
– volume: 3
  start-page: 179
  year: 2002
  ident: B111
  article-title: Genetics of myeloid leukemias
  publication-title: Annu Rev Genomics Hum Genet
  doi: 10.1146/annurev.genom.3.032802.115046
– volume: 110
  start-page: 2242
  issue: 7
  year: 2007
  ident: B246
  article-title: Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia
  publication-title: Blood
  doi: 10.1182/blood-2007-03-066936
– volume: 13
  start-page: 936
  issue: 9
  year: 2012
  ident: B91
  article-title: Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(12)70377-7
– volume: 118
  start-page: 4174
  issue: 15
  year: 2011
  ident: B190
  article-title: Pre-B cell receptor-mediated activation of BCL6 induces pre-B cell quiescence through transcriptional repression of MYC
  publication-title: Blood
  doi: 10.1182/blood-2011-01-331181
– volume: 68
  start-page: 9809
  issue: 23
  year: 2008
  ident: B180
  article-title: Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-08-1008
– volume: 32
  start-page: 720
  issue: 3
  year: 2002
  ident: B113
  article-title: Ikaros is critical for B cell differentiation and function
  publication-title: Eur J Immunol
  doi: 10.1002/1521-4141(200203)32:3720::AID-IMMU7203.0.CO;2-P
– volume: 95
  start-page: 793
  issue: 6
  year: 1998
  ident: B58
  article-title: Mammalian Grb2 regulates multiple steps in embryonic development and malignant transformation
  publication-title: Cell
  doi: 10.1016/S0092-8674(00)81702-X
– volume: 14
  start-page: e205
  issue: 6
  year: 2013
  ident: B206
  article-title: Relapsed childhood acute lymphoblastic leukaemia
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(12)70580-6
– volume: 24
  start-page: 460
  issue: 3
  year: 2006
  ident: B159
  article-title: High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2005.03.2177
– volume: 208
  start-page: 2163
  issue: 11
  year: 2011
  ident: B189
  article-title: BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia
  publication-title: J Exp Med
  doi: 10.1084/jem.20110304
– volume: 109
  start-page: 1408
  issue: 4
  year: 2007
  ident: B162
  article-title: Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study
  publication-title: Blood
  doi: 10.1182/blood-2006-03-011908
– volume: 8
  start-page: e70608
  issue: 8
  year: 2013
  ident: B63
  article-title: Small molecule ErbB inhibitors decrease proliferative signaling and promote apoptosis in Philadelphia chromosome-positive acute lymphoblastic leukemia
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0070608
– volume: 109
  start-page: 3676
  issue: 9
  year: 2007
  ident: B156
  article-title: Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell’Adulto (GIMEMA) LAL0201-B protocol
  publication-title: Blood
  doi: 10.1182/blood-2006-10-052746
– volume: 55
  start-page: 18
  issue: 1
  year: 2010
  ident: B235
  article-title: Imatinib mesylate in children and adolescents with cancer
  publication-title: Pediatr Blood Cancer
  doi: 10.1002/pbc.22484
– volume: 1
  start-page: 479
  issue: 5
  year: 2002
  ident: B62
  article-title: Critical role for Gab2 in transformation by BCR/ABL
  publication-title: Cancer Cell
  doi: 10.1016/S1535-6108(02)00074-0
– volume: 26
  start-page: 1475
  issue: 7
  year: 2012
  ident: B42
  article-title: Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia
  publication-title: Leukemia
  doi: 10.1038/leu.2012.5
– volume: 96
  start-page: 552
  issue: 4
  year: 2011
  ident: B171
  article-title: Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis
  publication-title: Haematologica
  doi: 10.3324/haematol.2010.034173
– volume: 82
  start-page: 981
  issue: 6
  year: 1995
  ident: B44
  article-title: Alternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogene
  publication-title: Cell
  doi: 10.1016/0092-8674(95)90277-5
– volume: 113
  start-page: 985
  issue: 5
  year: 2008
  ident: B165
  article-title: Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors
  publication-title: Cancer
  doi: 10.1002/cncr.23666
– volume: 27
  start-page: 3194
  issue: 22
  year: 2008
  ident: B51
  article-title: BCR-ABL oncogenic transformation of NIH 3T3 fibroblasts requires the IL-3 receptor
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1210979
– volume: 36
  start-page: 453
  issue: 5
  year: 2004
  ident: B47
  article-title: Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia
  publication-title: Nat Genet
  doi: 10.1038/ng1343
– volume: 45
  start-page: 242
  issue: 3
  year: 2013
  ident: B200
  article-title: The genomic landscape of hypodiploid acute lymphoblastic leukemia
  publication-title: Nat Genet
  doi: 10.1038/ng.2532
– volume: 376
  start-page: 263
  issue: 6537
  year: 1995
  ident: B129
  article-title: Failure of B-cell differentiation in mice lacking the transcription factor EBF
  publication-title: Nature
  doi: 10.1038/376263a0
– volume: 11
  start-page: 35
  year: 1998
  ident: B237
  article-title: Bone and mineral abnormalities in childhood acute lymphoblastic leukemia: influence of disease, drugs and nutrition
  publication-title: Int J Cancer Suppl
  doi: 10.1002/(SICI)1097-0215(1998)78:11+35::AID-IJC113.3.CO;2-9
– volume: 103
  start-page: 1495
  issue: 4
  year: 2004
  ident: B164
  article-title: Early prediction of response in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) treated with imatinib
  publication-title: Blood
  doi: 10.1182/blood-2003-01-0154
– volume: 122
  start-page: 6
  issue: 1
  year: 2009
  ident: B242
  article-title: Second-generation tyrosine kinase inhibitors in the post-transplant period in patients with chronic myeloid leukemia or Philadelphia-positive acute lymphoblastic leukemia
  publication-title: Acta Haematol
  doi: 10.1159/000228587
– volume: 22
  start-page: 153
  issue: 2
  year: 2012
  ident: B75
  article-title: Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia
  publication-title: Cancer Cell
  doi: 10.1016/j.ccr.2012.06.005
– volume: 110
  start-page: 2309
  issue: 7
  year: 2007
  ident: B220
  article-title: Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study
  publication-title: Blood
  doi: 10.1182/blood-2007-02-073528
– volume: 27
  start-page: 5202
  issue: 31
  year: 2009
  ident: B94
  article-title: IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2008.21.6408
– volume: 98
  start-page: 597
  issue: 4
  year: 2013
  ident: B101
  article-title: Breakpoint-specific multiplex polymerase chain reaction allows the detection of IKZF1 intragenic deletions and minimal residual disease monitoring in B-cell precursor acute lymphoblastic leukemia
  publication-title: Haematologica
  doi: 10.3324/haematol.2012.073965
– volume: 10
  start-page: 331
  issue: 4
  year: 2006
  ident: B56
  article-title: Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance
  publication-title: Cancer Cell
  doi: 10.1016/j.ccr.2006.09.006
– volume: 99
  start-page: 472
  issue: 2
  year: 2002
  ident: B126
  article-title: Multiple hematopoietic cell lineages develop in vivo from transplanted Pax5-deficient pre-B I-cell clones
  publication-title: Blood
  doi: 10.1182/blood.V99.2.472
– volume: 96
  start-page: 664
  issue: 2
  year: 2000
  ident: B29
  article-title: The Grb2 binding site is required for the induction of chronic myeloid leukemia-like disease in mice by the Bcr/Abl tyrosine kinase
  publication-title: Blood
  doi: 10.1182/blood.V96.2.664
– volume: 99
  start-page: 2760
  issue: 8
  year: 2002
  ident: B125
  article-title: Extensive in vivo self-renewal, long-term reconstitution capacity, and hematopoietic multipotency of Pax5-deficient precursor B-cell clones
  publication-title: Blood
  doi: 10.1182/blood.V99.2.472
– volume: 183
  start-page: 811
  issue: 3
  year: 1996
  ident: B49
  article-title: Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl
  publication-title: J Exp Med
  doi: 10.1084/jem.183.3.811
– volume: 112
  start-page: 4178
  issue: 10
  year: 2008
  ident: B202
  article-title: Genome-wide copy number profiling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemia
  publication-title: Blood
  doi: 10.1182/blood-2008-06-165027
– volume: 89
  start-page: 282
  issue: 3
  year: 2013
  ident: B223
  article-title: Phase II trial of HyperCVAD and Dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia
  publication-title: Am J Hematol
  doi: 10.1002/ajh.23624
– volume: 97
  start-page: 572
  issue: 2
  year: 2001
  ident: B145
  article-title: Hemizygous p16(INK4A) deletion in pediatric acute lymphoblastic leukemia predicts independent risk of relapse
  publication-title: Blood
  doi: 10.1182/blood.V97.2.572
– volume: 118
  start-page: 6521
  issue: 25
  year: 2011
  ident: B172
  article-title: Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
  publication-title: Blood
  doi: 10.1182/blood-2011-05-351403
– volume: 27
  start-page: 295
  issue: 2
  year: 2013
  ident: B150
  article-title: Prognostic value of genetic alterations in children with first bone marrow relapse of childhood B-cell precursor acute lymphoblastic leukemia
  publication-title: Leukemia
  doi: 10.1038/leu.2012.155
– volume: 117
  start-page: 2658
  issue: 9
  year: 2011
  ident: B208
  article-title: ETV6/RUNX1-positive relapses evolve from an ancestral clone and frequently acquire deletions of genes implicated in glucocorticoid signaling
  publication-title: Blood
  doi: 10.1182/blood-2010-03-275347
– volume: 38
  start-page: 379
  issue: 6
  year: 2002
  ident: B179
  article-title: In vitro drug resistance profile of Philadelphia positive acute lymphoblastic leukemia is heterogeneous and related to age: a report of the Dutch and German Leukemia Study Groups
  publication-title: Med Pediatr Oncol
  doi: 10.1002/mpo.10087
– volume: 121
  start-page: 485
  issue: 3
  year: 2013
  ident: B76
  article-title: Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: a report from the Children’s Oncology Group TARGET Project
  publication-title: Blood
  doi: 10.1182/blood-2012-04-422691
– volume: 190
  start-page: 1201
  issue: 9
  year: 1999
  ident: B103
  article-title: Defects in hemopoietic stem cell activity in Ikaros mutant mice
  publication-title: J Exp Med
  doi: 10.1084/jem.190.9.1201
– volume: 2
  start-page: 95
  issue: 2
  year: 2006
  ident: B36
  article-title: Allosteric inhibitors of Bcr-abl-dependent cell proliferation
  publication-title: Nat Chem Biol
  doi: 10.1038/nchembio760
– volume: 5
  start-page: 537
  issue: 6
  year: 1996
  ident: B102
  article-title: Selective defects in the development of the fetal and adult lymphoid system in mice with an Ikaros null mutation
  publication-title: Immunity
  doi: 10.1016/S1074-7613(00)80269-1
– volume: 342
  start-page: 998
  issue: 14
  year: 2000
  ident: B215
  article-title: Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia
  publication-title: N Engl J Med
  doi: 10.1056/NEJM200004063421402
– volume: 118
  start-page: 5559
  issue: 20
  year: 2011
  ident: B100
  article-title: Developmental origins and impact of BCR-ABL1 fusion and IKZF1 deletions in monozygotic twins with Ph+ acute lymphoblastic leukemia
  publication-title: Blood
  doi: 10.1182/blood-2011-07-366542
– volume: 350
  start-page: 1617
  issue: 16
  year: 2004
  ident: B196
  article-title: Prognostically useful gene-expression profiles in acute myeloid leukemia
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa040465
– volume: 344
  start-page: 1031
  issue: 14
  year: 2001
  ident: B12
  article-title: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
  publication-title: N Engl J Med
  doi: 10.1056/NEJM200104053441402
– volume: 243
  start-page: 290
  issue: 5405
  year: 1973
  ident: B20
  article-title: Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining
  publication-title: Nature
  doi: 10.1038/243290a0
– volume: 67
  start-page: 459
  issue: 3
  year: 1991
  ident: B30
  article-title: The BCR gene encodes a novel serine/threonine kinase activity within a single exon
  publication-title: Cell
  doi: 10.1016/0092-8674(91)90521-Y
– volume: 26
  start-page: 344
  issue: 4
  year: 2012
  ident: B154
  article-title: Haploinsufficiency of Dnmt1 impairs leukemia stem cell function through derepression of bivalent chromatin domains
  publication-title: Genes Dev
  doi: 10.1101/gad.184341.111
– volume: 83
  start-page: 289
  issue: 2
  year: 1995
  ident: B109
  article-title: A dominant mutation in the Ikaros gene leads to rapid development of leukemia and lymphoma
  publication-title: Cell
  doi: 10.1016/0092-8674(95)90170-1
– volume: 23
  start-page: 1989
  issue: 11
  year: 2009
  ident: B121
  article-title: PAX5 mutations occur frequently in adult B-cell progenitor acute lymphoblastic leukemia and PAX5 haploinsufficiency is associated with BCR-ABL1 and TCF3-PBX1 fusion genes: a GRAALL study
  publication-title: Leukemia
  doi: 10.1038/leu.2009.135
– volume: 42
  start-page: 492
  issue: 6
  year: 2010
  ident: B89
  article-title: Variation in CDKN2A at 9p21.3 influences childhood acute lymphoblastic leukemia risk
  publication-title: Nat Genet
  doi: 10.1038/ng.585
– volume: 8
  start-page: 2217
  issue: 7
  year: 2002
  ident: B146
  article-title: DNA methylation of multiple promoter-associated CpG islands in adult acute lymphocytic leukemia
  publication-title: Clin Cancer Res
– volume: 8
  start-page: 463
  issue: 5
  year: 2007
  ident: B122
  article-title: Pax5: the guardian of B cell identity and function
  publication-title: Nat Immunol
  doi: 10.1038/ni1454
– volume: 3
  start-page: 1
  issue: 1
  year: 2013
  ident: B86
  article-title: Function of Ikaros as a tumor suppressor in B cell acute lymphoblastic leukemia
  publication-title: Am J Blood Res
– reference: 21707583 - Br J Haematol. 2011 Sep;154(5):600-11
– reference: 23715577 - J Clin Oncol. 2013 Jul 1;31(19):2460-8
– reference: 12637609 - N Engl J Med. 2003 Mar 13;348(11):994-1004
– reference: 19204709 - Bone Marrow Transplant. 2009 Aug;44(3):169-74
– reference: 15509806 - Mol Cell Biol. 2004 Nov;24(22):10058-71
– reference: 21298759 - Pediatr Blood Cancer. 2011 Apr;56(4):671-3
– reference: 20445578 - Leukemia. 2010 Jul;24(7):1258-64
– reference: 12194988 - Annu Rev Genomics Hum Genet. 2002;3:179-98
– reference: 7553858 - Cell. 1995 Sep 22;82(6):981-8
– reference: 20207529 - Curr Opin Immunol. 2010 Apr;22(2):177-84
– reference: 23212150 - Leukemia. 2013 Jun;27(6):1254-62
– reference: 17851532 - Nature. 2007 Sep 27;449(7161):473-7
– reference: 8246975 - Mol Cell Biol. 1993 Dec;13(12):7587-95
– reference: 24291004 - Cancer Cell. 2013 Dec 9;24(6):766-76
– reference: 18366061 - Int J Cancer. 2008 Jun 15;122(12):2744-52
– reference: 15155841 - Mol Pharmacol. 2004 Jun;65(6):1485-95
– reference: 19878872 - Cancer Cell. 2009 Nov 6;16(5):401-12
– reference: 14427847 - J Natl Cancer Inst. 1960 Jul;25:85-109
– reference: 20131302 - Am J Hematol. 2010 Mar;85(3):164-70
– reference: 20798787 - Genes Cancer. 2010 Apr;1(4):346-59
– reference: 21183952 - Leukemia. 2011 Mar;25(3):463-72
– reference: 16618932 - Proc Natl Acad Sci U S A. 2006 Apr 25;103(17):6688-93
– reference: 22955920 - Blood. 2012 Oct 25;120(17 ):3510-8
– reference: 12573439 - Curr Opin Genet Dev. 2003 Feb;13(1):77-83
– reference: 16822902 - Blood. 2006 Jul 15;108(2):711-7
– reference: 14724652 - Leukemia. 2004 Mar;18(3):401-8
– reference: 19587702 - Leukemia. 2009 Nov;23 (11):1989-98
– reference: 19825449 - Hematol Oncol Clin North Am. 2009 Oct;23(5):991-1010, v
– reference: 18794796 - Oncogene. 2008 Nov 27;27(56):7055-69
– reference: 14551133 - Blood. 2004 Jun 15;103(12):4396-407
– reference: 22897847 - Cancer Cell. 2012 Aug 14;22(2):153-66
– reference: 12509383 - Blood. 2003 Jan 15;101(2):690-8
– reference: 24013638 - Nat Genet. 2013 Oct;45(10 ):1226-31
– reference: 21072043 - Leukemia. 2011 Feb;25(2):305-12
– reference: 23235717 - Leukemia. 2013 Apr;27(4):852-60
– reference: 18519632 - Genes Dev. 2008 Jun 1;22(11):1411-5
– reference: 17344859 - Nature. 2007 Apr 12;446(7137):758-64
– reference: 23604230 - Leukemia. 2013 Sep;27(9):1939-40
– reference: 16034462 - Leukemia. 2005 Sep;19(9):1509-16
– reference: 11287973 - N Engl J Med. 2001 Apr 5;344(14):1038-42
– reference: 19837270 - Cancer Genet Cytogenet. 2009 Nov;195(1):59-65
– reference: 11929787 - Blood. 2002 Apr 15;99(8):2957-68
– reference: 23835704 - J Clin Oncol. 2013 Sep 1;31(25):e413-6
– reference: 20452982 - J Biol Chem. 2010 Jul 9;285(28):21446-57
– reference: 17785208 - Cancer Cell. 2007 Sep;12 (3):280-92
– reference: 8940193 - J Biol Chem. 1996 Dec 6;271(49):31704-10
– reference: 11805317 - Proc Natl Acad Sci U S A. 2002 Jan 22;99(2):602-7
– reference: 20525995 - N Engl J Med. 2010 Jun 17;362(24):2260-70
– reference: 19684603 - Nat Genet. 2009 Sep;41(9):1001-5
– reference: 23936456 - PLoS One. 2013 Aug 01;8(8):e70608
– reference: 24779033 - Am J Hematol. 2014 Mar;89(3):282-7
– reference: 21593872 - Nature. 2011 May 19;473(7347):384-8
– reference: 17114238 - Cancer Res. 2006 Dec 1;66(23):11314-22
– reference: 2496972 - EMBO J. 1989 Jan;8(1):137-47
– reference: 23212523 - Blood. 2013 Jan 17;121(3):485-8
– reference: 11964322 - Blood. 2002 May 1;99(9):3472-5
– reference: 19075254 - J Clin Oncol. 2009 Jan 20;27(3):469-71
– reference: 15070699 - Blood. 2004 Apr 15;103(8):3167-74
– reference: 12592324 - Leukemia. 2003 Feb;17(2):283-9
– reference: 11984797 - Med Pediatr Oncol. 2002 Jun;38(6):379-86
– reference: 15789066 - Leukemia. 2005 May;19(5):713-20
– reference: 11535511 - Blood. 2001 Sep 15;98(6):1773-81
– reference: 21177505 - JAMA. 2010 Dec 22;304(24):2706-15
– reference: 15589172 - Immunity. 2004 Dec;21(6):843-51
– reference: 19129520 - N Engl J Med. 2009 Jan 29;360(5):470-80
– reference: 20876426 - J Clin Oncol. 2010 Nov 1;28(31):4755-61
– reference: 22299775 - Br J Haematol. 2012 May;157(4):507-10
– reference: 15462611 - Am J Pharmacogenomics. 2004;4(5):331-41
– reference: 7596184 - Leukemia. 1995 Jun;9(6):955-9
– reference: 12411494 - EMBO J. 2002 Nov 1;21(21):5766-74
– reference: 22868967 - Leukemia. 2013 Feb;27(2):503-7
– reference: 21730355 - Blood. 2011 Aug 25;118(8):2211-21
– reference: 23550147 - Cancer Discov. 2013 Apr;3(4):388-98
– reference: 17638918 - Cancer Res. 2007 Jul 15;67(14):7045-53
– reference: 19770381 - J Clin Oncol. 2009 Nov 1;27(31):5202-7
– reference: 11154239 - Blood. 2001 Jan 15;97(2):572-4
– reference: 12447959 - Am J Hematol. 2002 Dec;71(4):291-9
– reference: 21193419 - Haematologica. 2011 Apr;96(4):552-7
– reference: 12714971 - Nature. 2003 May 15;423(6937):302-5
– reference: 11781227 - Blood. 2002 Jan 15;99(2):472-8
– reference: 21765975 - World J Biol Chem. 2011 Jun 26;2(6):108-14
– reference: 18577747 - J Natl Cancer Inst. 2008 Jul 2;100(13):926-39
– reference: 11929764 - Blood. 2002 Apr 15;99(8):2760-6
– reference: 7542362 - Nature. 1995 Jul 20;376(6537):263-7
– reference: 22699455 - Leukemia. 2013 Feb;27(2):295-304
– reference: 7585946 - Cell. 1995 Oct 20;83(2):289-99
– reference: 12393636 - Blood. 2003 Jan 15;101(2):664-72
– reference: 22368272 - Blood. 2012 Apr 12;119(15):3512-22
– reference: 9407116 - J Biol Chem. 1997 Dec 26;272(52):33260-70
– reference: 18500345 - Nat Immunol. 2008 Jul;9(7):810-9
– reference: 16819511 - Oncogene. 2007 Jan 11;26(2):224-33
– reference: 8001127 - Cell. 1994 Dec 2;79(5):901-12
– reference: 16638934 - Blood. 2006 Sep 1;108(5):1469-77
– reference: 16304379 - Hematology Am Soc Hematol Educ Program. 2005;:188-94
– reference: 16344315 - J Clin Oncol. 2006 Jan 20;24(3):460-6
– reference: 20466853 - Blood. 2010 Sep 23;116(12):2070-7
– reference: 9737691 - Leukemia. 1998 Sep;12(9):1417-21
– reference: 15084694 - N Engl J Med. 2004 Apr 15;350(16):1617-28
– reference: 17496201 - Blood. 2007 Oct 1;110(7):2309-15
– reference: 21911423 - J Exp Med. 2011 Oct 24;208(11):2163-74
– reference: 10544193 - J Exp Med. 1999 Nov 1;190(9):1201-14
– reference: 17496200 - Blood. 2007 Oct 1;110(7):2242-9
– reference: 2005881 - Mol Cell Biol. 1991 Apr;11(4):1785-92
– reference: 24241490 - Haematologica. 2014 Apr;99(4):706-14
– reference: 8402896 - Cell. 1993 Oct 8;75(1):175-85
– reference: 23226581 - Genes Cancer. 2012 May;3(5-6):436-46
– reference: 11735629 - Drugs. 2001;61(12):1775-1776
– reference: 20453839 - Nat Genet. 2010 Jun;42(6):492-4
– reference: 18674933 - Immunity. 2008 Aug 15;29(2):217-27
– reference: 16493008 - Blood. 2006 Jun 15;107(12):4898-906
– reference: 19801979 - Nat Genet. 2009 Nov;41(11):1207-15
– reference: 12663457 - Blood. 2003 Jul 15;102(2):659-61
– reference: 21390130 - Nature. 2011 Mar 10;471(7337):235-9
– reference: 1657398 - Cell. 1991 Nov 1;67(3):459-68
– reference: 1875948 - Mol Cell Biol. 1991 Sep;11(9):4710-6
– reference: 19131438 - N Engl J Med. 2009 Jan 29;360(5):524-6
– reference: 23526495 - Am J Hematol. 2013 Jun;88(6):534-5
– reference: 19345118 - Immunity. 2009 Apr 17;30(4):493-507
– reference: 21299459 - Leuk Lymphoma. 2011 Feb;52 Suppl 1:45-53
– reference: 2408149 - Science. 1990 Mar 2;247(4946):1079-82
– reference: 20534699 - Haematologica. 2010 Oct;95(10 ):1683-90
– reference: 9876475 - Int J Cancer Suppl. 1998;11:35-9
– reference: 23065506 - Haematologica. 2013 Apr;98(4):597-601
– reference: 18768390 - Blood. 2008 Nov 15;112(10):4178-83
– reference: 12783368 - Semin Hematol. 2003 Apr;40(2 Suppl 2):4-10
– reference: 24180494 - N Engl J Med. 2013 Nov 7;369(19):1783-96
– reference: 23508010 - Haematologica. 2013 Jul;98 (7):1081-8
– reference: 8616716 - Nat Med. 1996 May;2(5):561-6
– reference: 15970668 - Cancer Biol Ther. 2005 Jul;4(7):747-52
– reference: 15251980 - Blood. 2004 Nov 1;104(9):2940-2
– reference: 23639321 - Lancet Oncol. 2013 May;14(6):e205-17
– reference: 21889209 - Leuk Res. 2011 Nov;35(11):1534-6
– reference: 2725497 - Mol Cell Biol. 1989 Mar;9(3):1263-70
– reference: 22359103 - Int J Hematol. 2012 Apr;95(4):409-19
– reference: 18704194 - J Clin Invest. 2008 Sep;118(9):3038-50
– reference: 10849448 - J Biol Chem. 2000 Jun 16;275(24):18581-5
– reference: 18071309 - Oncogene. 2008 May 15;27(22):3194-200
– reference: 17062730 - Blood. 2007 Feb 15;109(4):1408-13
– reference: 11870616 - Eur J Immunol. 2002 Mar;32(3):720-30
– reference: 1985699 - Blood. 1991 Jan 15;77(2):324-30
– reference: 18927431 - Blood. 2009 Apr 9;113(15):3397-405
– reference: 10366784 - Nat Immun. 1998;16(4):137-45
– reference: 20486169 - Pediatr Blood Cancer. 2010 Jul 15;55(1):18-25
– reference: 4126434 - Nature. 1973 Jun 1;243(5405):290-3
– reference: 24112092 - Eur J Haematol. 2014 Feb;92(2):111-20
– reference: 11314042 - Oncogene. 2001 Mar 1;20(9):1052-62
– reference: 22230800 - Leukemia. 2012 Jul;26(7):1475-81
– reference: 15930265 - Cancer Res. 2005 Jun 1;65(11):4500-5
– reference: 18615627 - Cancer. 2008 Sep 1;113(5):985-94
– reference: 21224468 - Blood. 2011 Mar 3;117(9):2658-67
– reference: 20227268 - Curr Opin Immunol. 2010 Apr;22(2):168-76
– reference: 9442394 - Immunobiology. 1997 Dec;198(1-3):227-35
– reference: 19047160 - Cancer Res. 2008 Dec 1;68(23):9809-16
– reference: 2179728 - Nature. 1990 Mar 15;344(6263):251-3
– reference: 21873988 - Nat Med. 2011 Aug 28;17(9):1086-93
– reference: 18477770 - Blood. 2008 Aug 15;112(4):1005-12
– reference: 8986714 - Immunity. 1996 Dec;5(6):537-49
– reference: 10090949 - Blood. 1999 Apr 1;93(7):2380-5
– reference: 17077147 - Proc Natl Acad Sci U S A. 2006 Nov 7;103(45):16870-5
– reference: 23178377 - Exp Hematol. 2013 Mar;41(3):293-302.e1
– reference: 8642285 - J Exp Med. 1996 Mar 1;183(3):811-20
– reference: 23512250 - J Natl Cancer Inst. 2013 May 15;105(10):733-42
– reference: 16616046 - Semin Hematol. 2006 Apr;43(2):126-33
– reference: 21921043 - Blood. 2011 Nov 10;118(19):5218-26
– reference: 22898679 - Lancet Oncol. 2012 Sep;13(9):936-45
– reference: 23692655 - Leuk Res. 2013 Aug;37(8):936-42
– reference: 22345515 - Genes Dev. 2012 Feb 15;26(4):344-9
– reference: 17119111 - Blood. 2007 Apr 1;109(7):2791-3
– reference: 18235045 - Blood. 2008 Apr 1;111(7):3821-9
– reference: 15098032 - Nat Genet. 2004 May;36(5):453-61
– reference: 20566697 - Mol Cell Biol. 2010 Sep;30(17):4149-58
– reference: 11888894 - Cancer Res. 2002 Mar 1;62(5):1296-9
– reference: 20525993 - N Engl J Med. 2010 Jun 17;362(24):2251-9
– reference: 21931113 - Blood. 2011 Dec 15;118(25):6521-8
– reference: 2747638 - Mol Cell Biol. 1989 May;9(5):1866-74
– reference: 14576058 - Blood. 2004 Feb 15;103(4):1495-8
– reference: 24200646 - Blood Cells Mol Dis. 2014 Feb-Mar;52(2-3):140-5
– reference: 19684604 - Nat Genet. 2009 Sep;41(9):1006-10
– reference: 21946537 - Nat Med. 2011 Sep 25;17(10):1298-303
– reference: 20042726 - Blood. 2010 Mar 4;115(9):1765-7
– reference: 20595523 - Blood. 2010 Jul 1;115(26):5428-9
– reference: 21606506 - J Exp Med. 2011 Jun 6;208(6):1135-49
– reference: 17440452 - Nat Immunol. 2007 May;8(5):463-70
– reference: 12750728 - Hematol J. 2003;4(2):104-9
– reference: 18650450 - Blood. 2008 Nov 1;112(9):3847-55
– reference: 19589926 - Blood. 2009 Sep 3;114(10):2159-67
– reference: 22829135 - Blood Cancer J. 2011 Apr;1(4):e14
– reference: 23358883 - Am J Blood Res. 2013;3(1):1-13
– reference: 17189410 - Clin Cancer Res. 2006 Dec 15;12(24):7374-9
– reference: 19602874 - Acta Haematol. 2009;122(1):6-10
– reference: 17010674 - Cancer Cell. 2006 Oct;10(4):331-42
– reference: 23589674 - Blood. 2013 Jun 13;121(24):4821-31
– reference: 16838024 - Leukemia. 2006 Sep;20(9):1526-32
– reference: 12970785 - Leukemia. 2003 Sep;17 (9):1845-50
– reference: 11940649 - Mol Cell Biol. 2002 May;22(9):2906-17
– reference: 7923373 - Cell. 1994 Oct 7;79(1):143-56
– reference: 8758931 - Cancer Res. 1996 Aug 1;56(15):3589-96
– reference: 11287972 - N Engl J Med. 2001 Apr 5;344(14):1031-7
– reference: 12114423 - Clin Cancer Res. 2002 Jul;8(7):2217-24
– reference: 19805687 - J Clin Oncol. 2009 Nov 1;27(31):5175-81
– reference: 21680795 - Blood. 2011 Sep 15;118(11):3080-7
– reference: 23138184 - Leukemia. 2013 Jun;27(6):1411-3
– reference: 17213285 - Blood. 2007 May 1;109(9):3676-8
– reference: 10224280 - J Exp Med. 1999 May 3;189(9):1399-412
– reference: 2406902 - Science. 1990 Feb 16;247(4944):824-30
– reference: 16931177 - DNA Repair (Amst). 2006 Sep 8;5(9-10):1273-81
– reference: 22845486 - Paediatr Drugs. 2012 Oct 1;14(5):299-316
– reference: 11801308 - Cancer Genet Cytogenet. 2002 Jan 1;132(1):46-50
– reference: 20385364 - Cancer Cell. 2010 Apr 13;17(4):400-11
– reference: 16687713 - N Engl J Med. 2006 May 11;354(19):2006-13
– reference: 18776928 - Bone Marrow Transplant. 2009 Jan;43(2):107-13
– reference: 24441288 - Leukemia. 2014 Jul;28(7):1467-71
– reference: 1712671 - Cell. 1991 Jul 12;66(1):161-71
– reference: 18408710 - Nature. 2008 May 1;453(7191):110-4
– reference: 21960589 - Blood. 2011 Nov 17;118(20):5559-64
– reference: 10887132 - Blood. 2000 Jul 15;96(2):664-70
– reference: 21856866 - Blood. 2011 Oct 13;118(15):4174-8
– reference: 23921123 - J Clin Invest. 2013 Jul;123(7):3099-111
– reference: 22682059 - J Hematol Oncol. 2012 Jun 08;5:29
– reference: 17405907 - Blood. 2007 Jul 15;110(2):727-34
– reference: 19798092 - Leukemia. 2009 Dec;23(12):2242-7
– reference: 10749961 - N Engl J Med. 2000 Apr 6;342(14):998-1006
– reference: 15531467 - Haematologica. 2004 Nov;89(11):1399-401
– reference: 22496163 - Blood. 2012 May 31;119(22):5201-10
– reference: 21747090 - J Clin Oncol. 2011 Aug 10;29(23):3185-93
– reference: 9865697 - Cell. 1998 Dec 11;95(6):793-803
– reference: 20072125 - Nature. 2010 Jan 28;463(7280):501-6
– reference: 23334668 - Nat Genet. 2013 Mar;45(3):242-52
– reference: 15454481 - Blood. 2005 Feb 1;105(3):1348-54
– reference: 23435357 - Biochem Pharmacol. 2013 May 1;85(9):1219-26
– reference: 6960256 - Nature. 1982 Dec 23;300(5894):765-7
– reference: 12444544 - Oncogene. 2002 Nov 21;21(53):8075-88
– reference: 18809762 - Blood. 2008 Dec 15;112(13):5190-2
– reference: 8541551 - Blood. 1995 Dec 15;86(12):4603-11
– reference: 16415863 - Nat Chem Biol. 2006 Feb;2(2):95-102
– reference: 12124177 - Cancer Cell. 2002 Jun;1(5):479-92
– reference: 7718873 - Blood. 1995 Apr 15;85(8):2013-6
– reference: 22848414 - PLoS One. 2012;7(7):e40934
– reference: 10360377 - Leukemia. 1999 Jun;13(6):884-90
– reference: 19039135 - Science. 2008 Nov 28;322(5906):1377-80
– reference: 22134481 - Clin Cancer Res. 2011 Dec 1;17(23):7413-23
– reference: 23233570 - Hematology Am Soc Hematol Educ Program. 2012;2012:122-8
– reference: 9923679 - Nature. 1999 Jan 14;397(6715):164-8
– reference: 21263099 - J Clin Oncol. 2011 Mar 1;29(7):839-44
– reference: 8892675 - Leukemia. 1996 Nov;10(11):1724-30
– reference: 18455151 - Biochem Pharmacol. 2008 Jun 1;75(11):2080-91
– reference: 21248843 - Nature. 2011 Jan 20;469(7330):362-7
SSID ssj0000650103
Score 2.3717694
SecondaryResourceType review_article
Snippet The t(9;22)(q34;q11) or Philadelphia chromosome creates a BCR-ABL1 fusion gene encoding for a chimeric BCR-ABL1 protein. It is present in 3-4% of pediatric...
The t(9;22)(q34;q11) or Philadelphia chromosome creates a BCR–ABL1 fusion gene encoding for a chimeric BCR–ABL1 protein. It is present in 3–4% of pediatric...
The t(9;22)(q34;q11) or Philadelphia chromosome that creates a BCR-ABL1 fusion gene encoding for a chimeric BCR-ABL1 protein is present in 3-4% of pediatric...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 54
SubjectTerms Acute Lymphoblastic Leukemia
BCR-ABL1
chemotherapy
Hematopoietic Stem Cell Transplantation
Oncology
Tyrosine Kinase Inhibition
Title Current Concepts in Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
URI https://www.ncbi.nlm.nih.gov/pubmed/24724051
https://www.proquest.com/docview/1540117815
https://pubmed.ncbi.nlm.nih.gov/PMC3971203
https://doaj.org/article/292d723c96fc44089d81b560aaa39e37
Volume 4
WOSCitedRecordID wos000218397400052&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  customDbUrl:
  eissn: 2234-943X
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000650103
  issn: 2234-943X
  databaseCode: DOA
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVHPJ
  databaseName: ROAD: Directory of Open Access Scholarly Resources
  customDbUrl:
  eissn: 2234-943X
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000650103
  issn: 2234-943X
  databaseCode: M~E
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: https://road.issn.org
  providerName: ISSN International Centre
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3Pb9MwFH6CCSEuiPGzDCYjcRhCYYmd1PaxTJs4ZFMPIPVmJfarWo0m09pO4sLfvvfirGoRExcuOSS24nx-zvuef3wP4KOpyUeoUCS21iHJlfSJxTxL1JDcDdmz0dhJ5pf64sJMJna8leqL94RFeeAI3LG0MmipvB1OPWdHtoGIFrnpqqqURdWdIyfWsxVMxX9wwQkMopYPRWH2eNo2rFiYsVh2WuQ7bqhT6_8bxfxzp-SW6zl7Bk97zihGsa378ACb5_D4vF8VfwHYiyyJk3gGcSnmjdjk4BA8Z8JikFezeSVYDHfRLtsFinG3X-sGxcivVyjKX9SxbU1sml4jSlxf4oIqHI1nn8WoLD-9hB9np99PviV9-oTE54VdJdL42vgKyadPa4nWaF0Fr4LOc5umISNfTWwrxyDTYINlbymHdarQeOWJF6lXsNe0Db4BoXydoh9ScaJPNMhrEzzF1FMyQ2I0IRvAlzs0ne-1xTnFxU9HMQbD7xh-x_C7Dv4BHG0qXEVZjfuLfuXu2RRjPezuBlmJ663E_ctKBvDhrnMdjR9eFKkabNdLRxSSZfEIiwG8jp29eZXMNRGegj5P75jBTlt2nzTzWafRTTQvk6l6-z8afwBPGI448fMO9lbXa3wPj_zNar68PoSHemIOO_On6_nv01vljAkR
linkProvider Directory of Open Access Journals
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Current+concepts+in+pediatric+Philadelphia+chromosome-positive+acute+lymphoblastic+leukemia&rft.jtitle=Frontiers+in+oncology&rft.au=Bernt%2C+Kathrin+M&rft.au=Hunger%2C+Stephen+P&rft.date=2014-01-01&rft.issn=2234-943X&rft.eissn=2234-943X&rft.volume=4&rft.spage=54&rft_id=info:doi/10.3389%2Ffonc.2014.00054&rft_id=info%3Apmid%2F24724051&rft.externalDocID=24724051
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2234-943X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2234-943X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2234-943X&client=summon